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ABSTRACT

The nasal administration of drugs, particularly peptides, is very beneficial but
like other mucosal routes, suffers from low bioavailability for the higher
molecular weight compounds. The nasal bioavailability of peptides and proteins
is influenced by the dosage form as well as the devices used for administration.
In the present study an effort was made to investigate the effect of formulation

and device variables on the intranasal delivery and absorption of salmon
calcitonin (sCT). The formulations were designed as nasal sprays with viscosity
of 1 and 76 cps using methylcellulose as a viscosity enhancing agent at 0 and 1%
w /w; tonicity of 100 mOsm, 300 mOsm and 600 mOsm using sodium chloride as
a

tonicit y

adjusting

agent;

an

acidic

phospholipid,

Dimyristoylphosphatidylglycerol (DMPG), as an absorption enhancer at 1%
w /wand chlorobutanol as the preservative. The formulations were investigated
for viscosity by using a cone and plate viscometer and for droplet size
distribution with a Malvern laser sizer. The selected formulations were delivered
to the nasal cavity of healthy male New Zealand rabbits using a commercially
available metered spray pump and a prototype device, nasal micron spray
pump, to facilitate a uniform distribution of the spray in the nasal cavity. The
components of the devices, mechanism of pump and actuator design were
evaluated for dose accuracy as well as their ability to generate a uniform
distribution of spray in the nasal cavity. A full factorial design with tonicity at
three levels, viscosity at two levels and concentration of enhancer at two levels
was used as the experimental design. Serum levels of sCT were determined using
a double antibody radioimrnunoassay. The area under the curve (AUC) and
bioavailability were determined using pharrnacokinetic software MKDATA. The
pharmacodynamic effect of salmon calcitonin of lowering of calcium was

measured, by complexation with arsenazo III, using a visible spectrophotometric
technique at 650 nm. The data was analyzed using ANOVA and the comparisons
among the treatments were performed using• Scheffe's multiple comparison
analysis and Fisher's least significance test. Deviation from isotonicity (300
mOsm) enhanced the intranasal bioavailability of sCT by 4-5 fold while the
addition of DMPG at a concentration of 1% w /w doubled the bioavailability.
Variation in the viscosity of formulations did not influence the bioavailability of
salmon calcitonin. The data was interpreted using response surface methodology
(RSM) with canonical analysis parameters demonstrating that optimum
formulations could be designed.
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PREFACE

I elected to write this dissertation following the format of the manuscript plan
described in section 11-3 of the graduate manual at the University of Rhode
Island. This option was most appropriate to present my results in various
sections.

Section I consists of a general introduction of the topic and the objectives of my
investigation. The three manuscripts, in Section II are the core of this study.
Section III contains a set of appendices A to C giving experimental details and
supporting data for the three manuscripts presented in Section II.
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SECTION I

1

(

INTRODUCTION

2

Recent years have seen enormous advances in the field of protein and

(

peptide engineering and a greater understanding of the way in which
biological response modifiers function in the body. It is now possible through
the use of recombinant DNA techniques, or by solid phase protein synthesis,
to p roduce significant quantities of a wide variety of proteins and polypeptide
hormones that are therapeutically active. The list of these response modifiers
includes interferons, macrophage activation fa ctors, neuropeptides and
proteins that may have potential in cardiovascular diseases, inflammation,
' contraception etc Prospects of using some of these materials in medicine
h ave reached the stage where prod ucts have either been approved by
regulatory authorities or are the subject of applications as investigational
drugs or as new

~herapeutic

agents . In most cases thes e agents are

administered by injection, however those agents which are indicated for
chronic therapy need to be administered by appropriate delivery systems .

Unfortunately the research technology for development of delivery systems
for peptides and proteins has not kept pace with the rapid progress in
biotechnology and consequently there are presently few systems that are
entirely appropriate for the administration of macromolecules. Furthermore
essential pharmacokinetic and correlative pharmacodynamic data is often
missing, for example questions like where and how does the peptide
function?, what dose is needed and how often should it be given?.

Many of these obstacles are rela ted to the properties that set peptides and
p roteins apart from the vast majority of drug substances in use today. These
properties include molecular size, susceptibility to proteolytic breakdown,
rapid plasma clearance, peculiar dos e-resp onse curves, immunogenicity,

3

biocompatibility and the tendency of peptide or protein to undergo

(

aggregation, adsorption and denaturation. Therefore existing drug delivery
systems must be modified and novel ones must be developed to overcome
these obstaclesl.

Although the biotechnology industry has prompted a resurgence of interest
in noninvasive delivery systems, there have been studies performed as early
as 1922 investigating the efficacy of insulin by intranasal, oral, rectal and
vaginal routes2 . This early work and that of others up to the 1960's met with
little success. However these studies served to ill ustrate the major problems
of noninvasive delivery which are low bioavailability, unreliable dosing, and
acute local toxicity of formulations using permeation enhancers; these
problems still remain the major challenges3-7.

Some of the noninvasive routes investigated in the recent years are oral,
ocular, buccal, pulmonary, transdermal, rectal, vaginal and nasal. For each
route of delivery, there are two potential barriers to absorption, poor
permeability and enzymatic barriers. The problems of poor permeability, high
inter subject variability and acute toxicity associated with delivering protein
and peptide drugs by noninvasive routes may be minimized by using
enzymatic inhibitors and/ or novel absorption enhancers. The delivery by
these routes may not be bioequivalent to invasive methods, however the
convenience to patient will, in some cases, outweigh the demand for
complete bioequivalence8 .

The main emphasis is to rationally evaluate the problems for peptide and
protein drug delivery systems and the options available for rational and

4

optimal drug delivery.

Oral Delivery
A wide variety of routes of administration and delivery systems exist, but by
far the mos t popular approa ch is oral delivery where the drug is intended to
be absorbed from the gastrointestinal tract (GIT). However the delivery of
peptides and proteins v ia the GIT is difficult because of their inherent
instability due to the presence of proteolytic enzymes and the poor
permeability of the intestinal mucosa to high molecular weight polypeptides
and proteins9 .

Although generally unsuccessful at present, the potential therapeutic and
commercial benefits of successful oral delivery of peptides and proteins are
sufficiently compelling to sustain research. The principal strategy has been the
protection of a given peptide or protein from the proteolytic enzymes in the
lumen of the gastrointestinal tract. Insulin was encapsulated with an
impervious azopolymer film that remains intact in the GIT until it reaches
the large intestine. Once in the colon, the azo bonds of the polymer are
reduced by the indigenous microflora releasing the peptide. This strategy was
used for vasopressin and insulin and biologically active amounts were
absorbed into the blood stream of the rat. In spite of these encouraging results,
the general utility of this approach in oral delivery is far from certain and
requires additional information on the effects of both bacterial proteolytic
enzymes on peptide stability and fecal matter on peptide absorption within
the colonlO .

The less than successful delivery of oral dosage forms for proteins and

5

polypeptides has led to the investigation of alternative noninvasive routes

(

such as transdermal or mucosal routes. Peptides and proteins when delivered
via these alternative routes may be exposed to a smaller surface area, hence a
smaller fraction of enzymes are present, as compared to the oral route.
Peptides and proteins are subjected to less dilution via these routes since the
resident fluid volume is less, thereby maximizing the concentration gradient
for absorption .

Transdermal Delivery

The skin is composed of two major tissue layers . The outermost la yer of the
epidermis, the stratum corneum, is composed of thin flat, layered keratinized
cells, 15 to 20 layers thick and is major barrier to skin permeation. The
epidermis is much thinner than the dermis and is made up of stratified
keratinized cells. The underlying layer, or dermis is extensively vascularized
and contains a nerve network. While the stratum corneum lacks in enzymes,
the next viable layers contain numerous enzymes that can degrade peptide
and protein drugsll-12.

The transdermal route has been successful in systemically delivering small
drug molecules, such as scopolamine, nitroglycerine, clonidine, and estradiol.
The delivery of peptide and protein has shown a greater resistance to
absorption, primarily because of impermeability to the stratum corneum. At
the present time it seems highly unlikely that the simple application of a
peptide in a vehicle to the skin will produce suitable clinical effects13. The
enhancement of peptide/protein skin permeation via electric current,
iontophoresis, has shown some promise for the transdermal delivery of these
\

6

drugs. This mode of delivery may have the potential to deliver the drug in a
pulsaltile manner, which is critical for the desired physiological response of
some of the hormonal drugs14-15 .

However the iontophoretic transport of gonadotrophin-releasing hormone
(GnRH), produced erratic results16 . The LHRH analog, leuprolide, was
explored for iontophoretic facilitated transport and there was no measurable
flux at 0.SVl 7. Results obta ined with the thyrotropin releasing hormone in
nude mouse skin18 and insulin in albino rabbit skin19 indicated that
iontophoresis offers benefits only w hen the integrity of the stratum corneum
is compromised. In contrast, Siddiqui et al, reported iontophoretic facilitated
transport of insulin across the skin of diabetic rats without first stripping the
stratum corneum, although there were significant inter-animal variations in
the extent of blood glucose lowering20.

No explanation has been suggested for these discrepancies in the role of the
stratum corneum in limiting transdermal insulin absorption during
iontophoresis. These equivocal results, coupled with the uncertain long-term
effects of applied current on the skin cast doubt on the viability of
iontophoresis as a routine, noninvasive technique to improve transdermal
peptide and protein delivery21 .

Ocular Delivery
The visible part of the eye consists of the iris and the sclera. The iris is covered
by cornea and the sclera is covered by a conjunctiva! membrane. Absorption
primarily occurs through the cornea or the conjunctiva! membrane.

7

The systemic absorption of peptides and proteins may occur through contact

(

with the conjunctiva and the nasal mucosa , the latter occuring as the result of
drainage through the nasolacrimal duct. For optimal systemic delivery the
absorption through the conjuctival and n asal mucosa must be maximized.

The main difficulty in the delivery of drugs to the eye is the rapid removal of
the substances by blinking and drainage through the lacrimal duct and the
low

permeability

of

the

cornea22 . There is a significant level of

aminopeptid ases in the eye fluids and tissues which may degrade the
peptides23.

Several investigators have studied the deli very of peptides and proteins into
the systemic circulation by the ocular route24-29 . It has been demonstrated
that it is not possible to achieve therapeutic levels of insulin without the use
of a permeation enhancer. The bioavailability of insulin was improved by
coadministration of permeation enhancers such as polyoxyethylene-9-lauryl
ether, sodium deoxychlolate, sodium glycocholate. Over 80% of the insulin
reaching the systemic circulation was found to be absorbed through the nasal
mucosa and the absorption pattern followed that reported for nasal delivery
quite closely30. The coadministration of permeation enhancers offers
promising results but their long term effects on the ocular physiology and
histology need further characterization.

Pulmonary Delivery
Pulmonary delivery systems have also been considered as a method of
improving the bioavailability of peptide and proteins because of certain

8

advantageous features offered by the lung. The walls of the alveoli in the
deep lung are extremely thin (0.1 to 1 µm) as compared to the capillary walls
(7 µm) or red blood cells (8 µm) . They are an order of magnitude thinner than
typical mucosa! or epithelial membranes, which are several milllimeters
thick . In ad dition the surface area of the lung is extremely large,
approximatel y 75 m2 for a 70 kg male. Furthermore one puff of an aerosol
administered correctly can cover this surface area within seconds31.

However the lungs are rich in enzymes . Virtually all known peptide
hydrolases (exopeptidases and proteinases) are present in the lung tissue.
Several membrane-bound peptidases exist on pulmonary vascular surfaces
and a wide varie ty of proteinases are present in other lung cells. Several
peptidases are distributed throughout the lung and they may be impossible to
saturate and can cause rapid degradation of peptides32.

The particle size distribution of aerosolized drug is very critical to the
bioavailability of the aerosol formulations . The particle size often defined as
mass median aerodynamic diameter (MMAD), must be approximately 5 µm
or less in order for drug particles to reach lung. A major concern with aerosol
formulations is the denaturation of peptides and proteins during shaking and
aerosolization, the dispersibility, the particle size as well as the more common
concerns of chemical stability, safety and efficacy. A typical distribution of dose
delivered from a m etered dose inhaler indicated that only 4.7% of the
delivered dose actuall y r aches the peripheral lung and 6.3°/.1 reaches the
central lung33.

The absorption of the fraction of the drug that is able to reach the lung

9

depends upon factors singular to respiratory system, such as tidal volume,

(

respiratory rate, respiratory pause, respiratory distress syndrome, lung
volume, emboli, total lung burden, solubilization in alveolar macrophages,
recirculation, pancreatitis, exercise, interstitial lwi.g diseases etc34 . Thus a lot
of variables besides the formulation variables have to be taken into account
for optimal delivery by pulmonary route .

Buccal Delivery
The buccal membrane is similar to the skin in that it is a stratified squamous
epithelium, with cellular extrusion products filling the intercellular spaces.
The buccal enzymatic barrier is greater than other routes and enzyme activity
has been reported to be greater than at the vaginal or nasal mucosa.

However, the buccal route offers convenience and is generally more
acceptable to the patient than other routes. This route of delivery offers a
much larger and easily accessible area for placement of delivery systems such
as adhesive tablets, but there may be a risk of drug degradation by accidental
swallowing or by the salivary wash-out of the tablet. Therefore the preferred
dosage form for buccal delivery is bioadhesive patches. The formulation
aspects of bioadhesive patches include variables such as the type of polymers
used, the viscosity grade of the polymers, and the amount of polymer per
patch which can further aid in optimizing the formulation35 .

Permeability offered by buccal route is often poor as compared to other
mucosal routes. Investigation of the buccal delivery of protirelin indicated
the buccal dose required to achieve an equivalent pharmacodynarnic response

10

was about 200 times higher than that for iv injection of the peptide. Thus

(

bioadhesive patches alone may not improve bioavailability sufficiently to
reach therapeutic levels and may require the coadministration of permeation
enhancers36.

Rectal Delivery
The human rectum offers a surface area of 200 to 400 cm2 . It is abundant in
blood, lymphati c vessels, and microflora and has a fairly constant
environment with respect to temperature, pH, and viscosity of rectal fluid37.

The enzymatic degradation of model enkephalin peptides has been shown to
be greatest in rectum and an absorption enhancer is required to achieve
therapeutic levels .

The dosage forms for rectal delivery of peptides and proteins are usually more
conventional such as solutions, gels, and suppositories. Of these, gels are the
most efficient because they offer a proper balance between retention at the site
of administration and the rate of peptide release38. It was demonstrated that
the rectal bioavailability of [Asul, 7]-eel calcitonin in the rat was best from a
0.1 % polyacrylic acid gel when compared with other dosage forms such as

saline, a triglyceride fatty acid mixture base, and a polyethylene glycol 1000
base. Following administration, solutions tend to spread away from the
rectum into the ascending colon and from there into portal rather than
general circulation39 thereby resulting in reduced peptide and protein
bioavailability. Recently, more sophisticated systems such as the osmotic
pumps and hydrogel cylinders have been investigated as rate-controlled rectal

11

drug delivery systems, and while the results have been positive, these dosage

(

forms have not yet been tested with peptide and proteins40-41 .

There does not seem to be significant absorption via rectal route without the
use of a permeation enhancer as demonstrated by the delivery of desglycinamide arginine -vasopressin which when enhanced with STDHF
reached an optimum concentration of 4'Y.,42.

How ever the lack of acceptability of this route by many patients and the
interruption of delivery by defecation makes this route less desirable than
other routes43 .

Nasal Delivery
The epithelial cells of the nasal mucosa are covered with numerous
microvilli and increase the surface available for drug absorption. The nasal
cavity offers a high surface area of approximately 150 cm2 for absorption.
Furthermore the subepithelial layer is highly vascularized with large and
fenestrated capillaries specially designed for the rapid passage of fluid through
the vascular wall. The venous blood draining from the nose passes directly
into the systemic circulation and is well suited for the absorption of drugs that
are extensively metabolized44.

Nasal administra tion of nonpeptide drugs or peptides of ten residues or less
has been very successful. Some examples are oxytocin, vasopressin and its
analog desmopressin acetate (DDA VP); and luteinizing hormone-releasing
hormone (LHRH) and its superanalogs buserelin, leuprolide, and nafarelin.

12

However when the number of amino acids is increased to 20 or greater, as in
r

insulin, glucagon or growth hormone releasing hormone, low bioavailability
results except when delivered with an enhancer45-46.

The nasal bioavailability of peptides and proteins is influenced by the dosage
form as well as the technique of administration. The most popular dosage
form has been the aqueous solution, although gels, powders and
microspheres ha ve been investigated.

The nasal administration of drugs, particularly peptides, is very advantageous
but like other routes suffers from low bioa v ailability. To achieve
reproducibility with dosing and provide acceptable economy in the treatment,
a bioavailability of 1-2'X, for an expensive recombinant peptide must be
improved. It is necessary to optimize both the techniques of administration
and the nasal formulations to provide a sufficient level of drug absorption.

The optimal nasal absorption delivery system should be well tolerated,
inexpensive, should have low toxicity and reasonable bioavailability. Starch
microspheres, water insoluble and swellable powders and phospholipids are
novel absorption systems which have promising properties but need further
characterization47.

There are a number of noninvasive routes available for the delivery of
polypeptides and proteins but all suffer from the obvious disadvantage of
proteolytic activity and poor permeability to higher molecular weight
molecules. However, with the administration of either enzymes inhibitors or
protective polymers, or perhaps permeation enhancers, bioavailability can be

13

substantially improved. Even though bioavailability by these routes may still

(

be fairly low, the advantages of noninvasive therapy certainly outweigh the
disadvantages .

A comparison of different routes for the delivery of protirelin via nasal,
buccal, peroral and iv demonstrated that nasal administration was 10-times
more efficient than the buccal route. Based on the pharmacodynamic effects
observed, the nasal dose h ad to be five times higher than iv dose, whereas the
buccal dose had to be forty times the nasal dose48 .

Of all the alternative routes, the nasal route has received the most attention
to date . Nasal delivery has the potential of being an extremely effective route
for systemic administration of peptides and proteins . The selection of proper
formulation parameters such as the pH of the vehicle, buffer species and
concentration, ionic strength, viscosity, charge, osmolarity, type and
concentration of preservatives as well as delivery with an appropriate device
such as nasal spray pump, compressed air nebulizer, instillation catheter and
dry powder insufflator could further influence and optimize the absorption of
peptide and proteins.

14
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OBJECTIVES

(
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The objectives of the present research were:

1.

To identify the formulation and device variables that are critical in
enhancing the low intranasal absorption of the polypeptide, salmon
calcitonin.

2.

To systematically characterize the effect of formulation and device
variables on the droplet size distribution and dynamics of spray
profile.

3

To study the primary and interactive effects of varying levels of
viscosity and tonicity on the nasal absorption of salmon calcitonin.

4.

(

To study the effect of the novel absorption enhancer,
Dimyristoylphosphatidylglycerol (DMPG) on the absorption of salmon
ca lei tonin.

5.

To characterize the optimal calcium lowering response of salmon
calcitonin as a function of salt concentration, viscosity and concentration
of absorption enhancer, dimyristoylphosphatidylglycerol.

6.

To demonstrate the use of response surface methodology (RSM) as an
aid in determining optimal formulations .
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(
MANUSCRIPT I

EVALUATION OF FORMULATION AND DELIVERY DEVICE
VARIABLES ON NASAL SPRAY CHARACTERISTICS

(

I

\.
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ABSTRACT

(
The aim of this study was to evaluate the effect of formulation variables;
viscosity, tonicity, concentration of absorption enhancer and nasal delivery
devices; mechanical metered nasal spray pumps,. pump components and a
prototype device, the nasal micron spray pump on the spray characteristics
and dose administration of a model nasal product. Formulations were
prepared within specified ranges of viscosity (1 to 380 cps), tonicity (100, 300
and 600 mOsms) and absorption enhancer (0 and 0.5% w /w). Viscosity was
deter mined using a Brookfield cone and plate viscometer. The spray
characteristics of the formulations were analyzed with a Malvern laser sizer
and evaluated by characterizing the size distribution of the sprayed droplets
using MSO and M90 parameters. For the metered nasal spray pumps, results
indicated that among the formulation variables, increasing viscosity or

l

'\

addition of an absorption enhancer increased droplet size and produced a
deviation from a Gaussian size distribution of the sprayed droplets. It was not
possible to spray any solution greater than 2.12 cps and maintain .a Gaussian
spray distribution with a metered nasal spray pump. Tonicity did not
demonstrate any significant effect on the droplet size distribution. Changes in
pump based on two different mechanisms of spray delivery or actuator
assembly design based on the orifice diameter or spray angle of spray insert
did not produce any significant differences in spray characteristics. However
with the use of a prototype device, the nasal micron spray pump, it was
possible to spray solutions up to a viscosity of 76 cps as a fine spray.

Key words: Spray characteristics, Mal vern laser sizer, Metered nasal spray
pump, Formulation variables, Device variables, Nasal micron spray pump
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INTRODUCTION
(
>(

)( {§.everal types of delivery devices such as nasal pump sprayers, compressed air
nebulizers, instillation catheters and dry p owder insufflators are used to
adminis ter drugs to the nose. There are mechanistic variations in these
devices that produce d iffe rences in the delivery of a drug in terms of volume
and reproducibil it~

h e instillation catheter h as high accuracy but only a

small volume, less than 50 µ l, therefore limited doses can be delivered. An
aerosol spray can deliver higher volumes, up to 140 µl b u t the amount of
active ingredients delivered is limited b y d rug solub ility and viscosity. Dry
pow ders offer the option of delivering the highest m ass of active ingredients
because they may not fo rmulated to contain a carrier vehicle. Thus 100% of
mass delivered can be active ingredient. Reproducibility is also an important
factor . Administration by instillation catheter and compressed air nebulizer
have been shown to provide good reproducibility with respect to the amount
of material delivered. On the other hand administration by a nasal spray
pump or dry powder insufflator have been found to be considerably more
variable particularly with respect to amount of material deposited in the
nosel .

~ [These devices influence the mode in which the drug is administered, ie.,
whether the drug is delivered as drops, aerosol or spray. The mode of drug
administration can affect drug distribution in the nasal cavity, which in turn
influences bioavailability of a drug. It ha s been demonstrated that significant
differences in drug distribution were observed w hen drug was administered
by catheter, mechanical metered nasal sp ray pump and metered dose
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pressurized aerosol. The results indicated that the metered nasal spray pump
gave a constant dose and a very good nasal mucosa! distribution2, 3.

J»

,... Delivery devices as well as the density, shape, hygroscopicity of the particles
\...

and the particle size distribution affect the deposition site within the nasal
cavity. The deposition site in turn influences the extent and rate of absorption
which in turn is dependent on ciliary movement and/or diffusion in the
mucous layer and su sequently the biological response in experimental
'I

animals and hu man~§. uniform distribution of particles throughout the
nasal cavity may be achieved by delivering the particles from a nasal spray
using a pressurized propellant. A metered dose delivery system developed for
the nasal delivery of drugs could provide a consistent dose delivery and spray
pattern which affects the deposition of droplets in the nasal cavity. Metered
nasal spray devices have shown the ability to deposit well controlled doses in
the nasal cavity which remain there for sufficient period to provide complete
absorption4.J

#' ~xperimental

¥
work has demonstrated that the relative bioa~.~_ilability and

biologi5al response can be improved by adminstration of a drug via nasal
spray pumps rather than by nasal drops. Nose drops disperse the dose
throughout the length of the nasal cavity, from atrium to the nasopharynx.
The nasal spray deposits droplets anteriorly in the nasal cavity with little or
no dose reaching the turbinates. The drug deposited anteriorly in the nasal
cavity remained in the nose longer while drops are cleared more rapidly than

the dose administered as a sprays, 6.

J
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addition to the proper choice of nasal device, it is imperative that studies

be performed to select the variables such as concentration and volume of the
dose to be sprayed for optimum intranasal delivery. Nasal bioavailability has
been found to be a function of the volume and concentration of the nasal
spray. It has been demonstrated that a formulation administered by two 50 µl
sprays gave a biological response superior to that of same drug administered
by one 100 µl dose7 . Thus both administration devic~ and formulation
desi n can affect drug distribution, deposition and the clearance process from
the nasal cavity, leading to modifications in th biopharmaceutical aspects
and bioavailability of the drug administered ] 1'

Despite the fact that nasal delivery devices have been available for over a
decade there is still very little fundamental information as to how variations
in the design of a nasal pump assembly can interact with the formulation
variables and affect the dynamics of spray plume, droplet size, spray
deposition and distribution in the nasal cavity. This information along with
an understanding of nasal formulation parameters could aid in optimized
products designed to enhance bioavailability. This paper documents the nasal
devices and their interaction with the formulation variables.

In this study two types of nasal spray devices; a metered nasal spray pump and
its mechanical components i.e., mechanism of pump, design of actuator and a
prototype device, the nasal micron spray pump were studied.

The metered nasal spray pump is a d rug delivery device that administers a
predetermined volume of formulation into th e nasal cavity. It has been
successfully utilized commercially in the administration of several locally
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acting drugs, such as corticosteroids (Extr acort, Syntaris ), beclornethasone

(

dipropionate (Aldecin, Beconase, Becotide, Vancenase), flunisolide
(Nasalide), trarnazoline (Tobispray), and nasal decongestants (Rhinospray,
Otrivin, Afrin, Nostril, Nostrilla , Dris tan); and is also used for the systemic
delivery of calcitonin (Calcitonina, Calsynar), nafarelin acetate (Synarel),
crornolyn acetate (Nasalcrorn), insulin, desmopressin acetate, nitroglycerin.
A typical nasal spray pump is composed of 10-13 spray components, to include
metering chamber (5-7), actuator (2-3) and closure (2) components.

The metered nasal spray pump is available as (i) a ball and spring pump or (ii)
a dual spring compression pump. As the names suggest, these pumps use two
different mechanisms to aspirate the liquid from container and to release the
spray . The ball and spring pump is composed of a cylinder, shut off valve
(ball), spring, piston, stern, and a device for connection to the actuator. The
dual spring compression or precornpression pump is composed of piston,
diptube and twin springs; these twin springs help to aspirate the liquid from
container and also act as a shut off valve.

The actuator in a mechanical nasal spray pump aids in expelling the liquid
mass aspirated by the pump assembly or metering chamber. Actuators are
available as a one or two piece assembly and house a spray insert with a
specified diameter to expel the liquid as spray. When a pump is actuated, a
dose volume aliquot is released from the metering chamber and travels as a
liquid mass until it encounters the restriction of the orifice of the spray insert.
This restriction may have a series of spiral baffles, which begin the liquid
breakup and impart a spinning motion to the liquid resulting in the spray
mist. The spray pattern is determined by the number of spiral baffles and is
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used to produce a wide (50-700) or narrow (20-40°) spray cone. Droplet size is

(

dependent upon force of the liquid mass striking the orifice, plus the design
of the baffles, the diameter of the opening as well as the characteristics of the
liquid itself.

It has been previously demonstrated that the addition of a viscosity

enhancing agent increases contact time in the nose by reducing the rate of
mucociliary clearance of the dosage form and may help to enhance the
activ ity by increasing the "window" of absorption for the administered drug.
Viscosity also seems to change the pattern of deposition and clearances.
However previous studies have investigated viscosity in the range of 1-3.5
cps, which can be considered as low viscosity solutions. The nasal micron
spray pump (NMSP), a prototype device originally developed for
administration of pulmonary inhalation solutions (figure 1) was used in this
study to investigate the feasibility of using the device to deliver solutions of
higher viscosity to the nose. The NMSP is a hand actuated propellent free
spray device that is capable of producing a fine spray. The physical and
technical requirements have been achieved by using an air blast nozzle
(figure 2). The air blast nozzle is the heart of this spray device and its
geometry is mainly responsible for the ability to generate small droplets
especially for viscous solutions. The nozzle consists of a mixing chamber
whose volume is partly filled by a polyurethane sponge with open pores. The
NMSP also consists of two pumps, a liquid metering pump and an air pump.
When the device is actuated by turning the top part in a rotational motion, a
liquid volume is metered into the mixing chamber simultaneously. The
device is now primed . By pressing the actuation button the air valve opens

(

and air starts to flow through the nozzle and is compressed. This compressed
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air expands through the nozzle system with increasing velocity. The solution

(

is now accelerated by the expanding ambient air leaving the nozzle and the
kinetic energy of the air stream pushes and shears the liquid which was
previously dispersed in the sponge and thus disintegrates the liquid into
small droplets9

The geometry of air blast nozzle of the NMSP provides a huge improvement
as compared to the metered nasal spray pump which uses a mechanical
actuator to spray the liquid mass. The use of this new device for nasal
delivery could be in aluable for administering the drugs in high viscosity
solutions because it is able to generate a fine mist of spray for distribution into
the nasal cavity9 .

Nasal devices are capable of generating different spray profiles because of the
different types of components which makeup the functional unit. The
literature shows no investigation of the influence of nasal administration
device variables on spray characteristics. Likewise the spray characteristics
may also be affected by the formulation variables.

Since it is strongly postulated that the functional components of a nasal
pump assembly can interact with the formulation variables and affect the
dynamics of spray profile, spray deposition and distribution in the nasal
cavity; it was decided to evaluate the influence of the formulation variables:
viscosity, tonicity, concentration of absorption enhancer with the nasal
administration device variables : mechanism of pump (ball and spring versus
dual spring compression pump), design of actuator (orifice diameter of spray
insert, spray angle), on the spray characteristics and droplet size distribution.
(
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EXPERIMENTAL

(

Materials
Methylcellulose, Methocel A15C Premium (Dow Chemical Co., Midland, MI)
w as used as a viscosity enhancing agent in the concentration of 0.25%-2%
w /w. Sodium Chloride (Fisher Scientific, Fairlawn, NJ) was used to adjust
tonicity . Dimyristoylphosphatidylglycerol (Avanti Polar Lipids, Alabaster, AL)
was used in the concentration of 0.5% as absorption enhancer. Chlorbutanol
0.5% w /w (Sigma Chemical Co., St. Louis, MO) was used as a preservative.

Methodology
Selection of formulation variables
Viscosity
Methylcellulose (Methocel), a natural carbohydrate that contains a repeating
structure of anhydroglucose units was chosen as a viscosity enhancing agent.
It is odorless and colorless. The premium grade was chosen as it is a GRAS

substance and approved by FDA. Formulations containing methylcellulose
were prepared in concentrations ranging from 0.25% to 2%.

Tonicity
Tonicity was investigated at three levels using sodium chloride as a tonicity
adjusting agent. Formulations were prepared at 600 mOsms (hypertonic), 300
mOsm (isotonic) and 100 mOsms (hypotonic).

Absorption Enhancer
Dimyristoylphosphatidylglycerol, an acidic phospholipid, a novel permeation
enhancer was used at a concentration of 0.5% w /w .
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Preservative

(

Chlorbutanol, a lipophilic preservative, 0.5% w /w was used as a preservative.

Preparation of Formulations
The formulations were prepared with a concentration of methylcellulose
ranging from 0.25% to 2% in a sodium acetate-acetic acid buffer at pH 4.
Methylcellulose was dispered in hot water (90-95° C) and stirred until all the
particles were hydrated. Cold wa ter was added slowly to the above mixture,
the mixture was kept in an ice bath. The above dispersion was agitated for 3-4
hrs, the specified quantity of sodium chloride was added depending upon the
osmolarity required for the formulation and then stored in a refrigerator
overnight. The dispersion was brought to the pH 4 with buffer after bringing
it to the room temperature. All the formulations were filled into 4 ml clear,
round, Type I glass serum vials equipped with metered pumps.

Determination of Viscosity
The viscosity of all the formulations was determined using a Brookfield coneplate viscometer, Model DV II. This cone-plate viscometer is equipped with a
detachable "cone" and can be used with cones ranging from 0.8 to 30 radians.
Cone, CP 52D, diameter of 2.4 ems and a cone of 3° was selected to carry out
the viscosity determinations at 25°C. The viscometer was calibrated using
standards ranging from 1 to 500 cps. Viscosity was determined at rotational
speeds ranging from 0.5 to 100 rpm. Shear torque readings were recorded at
each rotational speed .
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Selection of delivery systems for intranasal drug admin istration
(

There has not been any investigation of the interaction of the components of
a spray pum p and the formulation v ariabl es on the spray profile and droplet
size distribution. The evaluation of the metered nasal spray pumps was
performed using the different available components of (i) pump mechanism
ie., ball and spring (Pfeiffer); dual spring compression (Valois) (ii) orifice
diameter of the actuator ie ., 0.1 mm, 0.3 mm and 0.7 mm and (iii) angle of
spray of the actuator ie., 200, 350, 60o.

Dose reproducibity studies
After priming of the pumps the weight loss per spray actuation was recorded
for 10 consecutive strokes and arithmetic mean and standard deviation were
calculated. Since these devices would later be used to administer the drug in
bioavailability studies and since the dose was to be administerd within a
interval of 60 minutes to the experimental animals, the dose accuracy was
measured after 1 hr to determine if a second priming stroke was required
before the second dose was administered. The procedure was also repeated,
after 24 hrs.

Screening of Nasal Devices
An initial qualitative screening was performed with formulations ranging in
viscosity (1 cps to 380 cps), tonicity (100, 300 and 600 mOsm) and concentration
of the absorption enhancer (0 and 0.5% w / w) in combination with the
various nasal device components such as the type of pump and actuator
design etc. The initial evaluation of the spray profile was obtained by spraying
against a background of black and white. The spray pattern was categorized as
a fine spray, stream or stream with drops . Only the nasal spray devices
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producing a fine spray were later used to d etermine the droplet size

(

distribution using a Malvern laser sizer.

--

----- -

_

-

D etermination of Droplet size using the Malvern laser sizer

---

...

...

.

The samples w ere anal yzed using a Malvern laser particle sizer (Malvern
t>iqll;aP ft. 3ooo c.ompuJe1...
Instruments, Inc., Southborough, MA)., equipped with a t.600c analy:~ing w•tH,
0-V'ld Dl61TAL. ~X6V CoIO..- N\On i+D.- . ~~two.re,: mo.tver'l rrtas~i i..ez.
NEC Powan:uate SX /1 6i computer._versi
Q.. Ga-t acE[tti'St-ion-soft-wcrr , a ~tuXJ..re.,
spray synchronizer (PS51), and infrared trigger sensor (PS57), NEC Multisync
2A monitor, and an O kida ta Microline 320 dot m atrix printer. An adjustable
m etal support bracke t, to hold samples, was machined by Trans American
Tool Co., Inc., Spring City, PA. The Malvern 2600c analyzing unit was
equipped with a 300 mm range lens and configured as shown in figure 3.
After performing a background measurement the sample bottle was
positioned in the support at a distance of 10 cm from the actuator to the tip to
the laser beam. The centerline of the bottle was 17 cm from the range lens. A
"measure sample" command was executed from the key board prior to the
actuation of the sample. Samples were actuated four times for each analysis.
The analysis was performed in triplicate. The computer system was
configured so that a total of 1000 sweeps (measurements) were executed
during each analysis . The computer sweeps the detector at a rate of
approximately 125 sweeps per second thereby giving the analyst sufficient
time (about eight seconds) to perform four actuations per sample analysis of
each sample.

Statistical Analysis
In order to determine the influence of the experimental variables on the
spray characteristics, the measured droplet size distributions were subjected to
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ANOVA. A completely randomized design was used. The analysis was

(

performed using Statistical Analysis Software (SAS) and subjected to an F Test
and hypothesis testing at 0.01 and 0.05 significance level. According to the
hypothesis testing it was assumed that there was no difference among the
droplet size measured and in cases where Fo was greater than F at 0.01 level
and

0.05

levels,

the

hypothesis

testing

was

rejected.

Scheffe's

multicomparison tes t were performed to further indicate significant
differences among groups.

RES ULTS AND DISCUSSION

Viscosity studies
The viscosity of the formulations varying in methylcellulose concentration
was determined using a Brookfield cone and plate viscometer. The flow
(

behavior was determined from a plot of shear rate versus shear stress(figure
4). Methylcellulose exhibited a non-Newtonian flow behavior. There was a
nonlinear relationship between the shear rate and shear stress for the
methylcellulose indicating a deviation from the Newtonian behavior. Thus
the viscosity was determined at a fixed rotational speed of 50 rpm. The
viscosity at 50 rpm was found to be 1 cps for formulations without
methylcellulose. The viscosity was calculated to be 2.12 cps, 11.35 cps, 76 and
380 cps for formulations containing 0.25% w/w, 0.5% w/w, 1% w/w and 2%
w /w of methylcellulose.

Qualitative screening of formulations
All prepared formulations were qualitatively screened. When the nasal
devices with various actuator designs were tested ie., the metered spray pump

(
40

,-.

,.---..,,

FIGURE 4 NON-NEWTONIAN FLOW EXHIBITED BY METHYLCELLULOSE
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using either a ball and spring mechanism or a dual spring compression
pump; the actuator designs with orifice diameters of spray insert of 0.1 mm,
0.3 mm and 0.7 mm and spray angle, 200, 350 and 600 ; all the test
combinations generated a fine spray when the buffer solution with a viscosity
of lcps or a 0.25% w /w methylcellulose formulation with a viscosity of 2.12
cps was spraye d. All the formul ations

arying in tonicity, 300 mOsm, 600

mOsm and 100 mOsm or concentra tion of absorption enhancer, 0% w /w and
0.5% w /w produced a fine sp ray. However w hen formulations w ith 0.5%
w / w methocel with a viscosity of 11.35 cps w ere tested with the various pump
and actuator d esigns; all the test combinations generated a mixture of spray
with drops.

Formulations, with a viscosity greater than 11.35 cps were investigated using
the (NMSP). It was determined that the NMSP was able to deliver all
formulations up to viscosity of 76 cps generated by the 1% w I w
methylcellulose as a fine spray. However the viscosity generated by 2% w /w
methylcelluilose (380 cps) and was released from the NMSP as a gel.

Dose accuracy studies
A total of 5-6 actuations were required to prime the metered nasal spray
pump and ten actuations were required to prime the NMSP. This was
determined b y m easuring the w eight loss per spray actuation for a
formulation possessing a mea n weight of SO m g fo r metered nasal spray
pump and of 35 mg for the NMSP. The stand ard deviation was found to be
±2% from the mean weight of the metered nasal spray pump and ±6% from
the mean weight of the NMSP immediately after priming the pump.
However, while the deviation for the metered nasal spray pump was found
(
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FIGURE 5

DOSE REPRODUCIBILITY STUDIES OF NASAL DE VICES
Metered Nasal Spray
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to be ±2% from the mean weight; the NMSP showed a slight loss of primed
F

value that increased the standard deviation to ±14% from the mean weight
after 24 hrs (figure 5).

Droplet size analysis
Metered nasal spray pump
When using a Malvern laser sizer to measure the droplet produced by spray
pump, the M5o and M9o seemed to best characterize the size distribution. The
parameter M5o represents average droplet size of 50% of the sprayed droplets
and M9o represents an average size of 90°/t, of the sprayed droplet. The M5o for
buffer formulations with a viscosity of 1 cps was 45.23±1.11 µm, and M9o was
68.41±7.94 µm . The M 50 for 0.25% methylcellulose formulation with an
increased viscosity of 2.12 cps was 56.97±3.45 µm and 130.22±13.59 µm for the
M90 range. When increasing the methylcellulose to a 0.5% the viscosity was
11.35 cps and the M 50 increased to 105.86±7.77 µm and the M 90 was
305.04±18.54 µm .

The influence of the formulation variable, viscosity, on the spray profile and
droplet size analysis (figure 6), demonstrated that the average droplet size
increased with higher concentrations of methylcellulose. However with this
increase in viscosity the profile of droplet size deviated from a Gaussian
distribution. An ANOVA of these formulations varying in viscosity indicated
a significant difference at the M so and at the M 90.

Scheffe's multiple

comparison test and Fisher's Least Significance test indicated that the droplet
size distribution obtained from 1 cps and 2.12 cps was significantly different
from the distribution produced by solutions with a viscosity of 11.35 cps. The
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FIGURE 6 THE INFLUENCE OF VISCOSITY ON THE DROPLET SIZE DISTRIBUTION

USING METERED NASAL SPRAY PUMP
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seen for the

M9o level tends

to produce a large standard deviation than that

Mso.

Isotonic formulations with a osmolarity of 300 mOsm generated a M so of
45.23±1.15 µm, and

M9o was

68.4±7.94 µm . Hypotonic formulations with a

osmolarity of 100 mOsm generated a

Mso of 45.07±0.34 µm

and

M9o was 76.32

±2.49 µm . Hypertonic formulations with a osmolarity of 600 mOsm generated
a

Mso

of 47.4±2.25 µm, and

M9o was

130.37±2.25 µm . Thus the formulations

varying in tonicity (figure 7) did not show any significant difference at

Mso

but did show a significant difference at M 90. Scheffe's multiple comparison
test indicated that the droplet size distribution at M 90 obtained from the
hypertonic formulation was significantly different from the isotonic and
hypotonic formulations. The exact reason for this difference is not known.

The addition of the absorption enhancer, Dimyristoylphosphatidylglycerol
(DMPG) to the formulation also showed an increase in the
(figure 8). The

Mso for

Mso

and

M9o

formulations without DMPG was 45.23±1.11 µm, and

M9o was 66.79±6.87 µm.

However the addition of 0.5% DMPG provided a

of 71.16±3.18 µm, and a

M9o of

Mso

133.07±0.79 µm. This increase may be due to

the fact that the phospholipid forms a dispersion as compared to the solution
seen for the previous formulations.

Formulations varying in the

concentration of absorption enhancer indicated a significant difference at

Mso

and at M90 as shown by the Scheffe's multiple comparison test at p<0.01.

Among the device variables, the droplet size distribution and spray profiles
for the two different designs of the nasal spray pump are shown in figure 9.
The

Mso

for buffer formulations sprayed with a ball and spring pump was
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FIGURE 7 THE INFLUENCE OF TONI CITY ON THE DROPLET SIZE DISTRIBUTION

USING METERED NASAL SPRAY PUMP
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FIGURE 8 THE INFLUENCE OF CONCENTRATION OF ABSORPTION ENHANCER ON

THE DROPLET SIZE DISTRIBUTION USING METERED NASAL SPRAY PUMP
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FIGURE 9 THE INFLUENCE OF MECHANISM OF PUMP ON THE DROPLET SIZE

DISTRIBUTION FOR METERED NASAL SPRAY PUMP
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44.37±0.459 µm, and the M 90 was 76.64±1.01 µm. The M so for buffer
formulations sprayed using a dual spring compression pump was 47.42±2.24
µm, and the Mgo was 106.54±35.22 µm. The influence of the orifice diameter
of the spray insert is shown in figure 10. The M so for buffer formulations
sprayed using an actuator with 0.1 mm spray insert was 45.23±1.15 µm and the

Mgo was 68.41±7.94 µrn . The M5o for buffer formulations sprayed using a
spray insert with a diameter of 0.3 mm was 45.64±0.34 µm, and the M9o was
77.45±2.81 µm . The M5o for buffer formulations sprayed with a spray insert
with a diameter of 0.7 mm was 47.40±2.25 µm and the M9o was 123.6±24.86
µm . Similarly the effect of spray angle is shown in figure 11. The Mso for
buffer formulations sprayed from an orifice with a spray angle of 20° was
45.28±1.05 µm and the Mgo was 67.51±7.94 µm. Using spray angle of 35° the

M5o for buffer formulations sprayed was 45.07±0.34µm, and the M9o was
76.56±2.4 µm. The Mso for buffer formulations sprayed with a spray angle of
600 was 47.57±3.4 µrn, and the M9o was 124.93±40.34 µm. Statistical analysis of
the results indicated that there was not any significant difference at 0.01 level;
between the M 50 and M 90 for two different design mechanisms for the
pumps, on three different · spray angles and the M 50 for the threes sizes of
spray inserts. However the M9o for the 0.7 mm orifice insert was found to be
significantly different from 0.1 mm and 0.3 mm.

The actuator and orifice diameter of the spray insert of metered nasal spray
pump that were designed to be able to facilitate breakdown of the higher
viscosity formulations from a stream to fine spray did not produce any
significant differences in the droplet size distributions. This study emphasized
the need to explore the effect of increased pressure on the higher viscosity
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FIGURE 11 THE INFLUENCE OF SPRAY ANGLE ON THE DROPLET SIZE DISTRIBUTION

USING METERED NASAL SPRAY PUMP
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FIGURE 10 I Ht: INt-LUENCE OF ORIFICE DIAMETER ON THE DROPLET SIZE

DISTRIBUTION FOR METERED NASAL SPRAY PUMP
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formulations. It was decided to evaluate the prototype nasal micron spray
pump.

Nasal micron spray pump
The nasal micron spray pump (NMSP) is a prototype device designed to
reduce the particle size distribution by using the increased pressure generated
by the of air blast nozzle. Since viscosity seemed to be the most influential
factor in the determi na tion of droplet size, the formulations varying in
viscosity were delivered using this new prototype spray pump and droplet
size determined. The NMSP was able generate a

Mso

of 53.27±3.38 µm and a

Mgo of 223.44±83.44 µm for a 1 cps buffer and also to deliver the 11.35 cps

(0.5%w /w) and 76 cps (1 % w /w) methylcellulose formulations with an
average

(

Mso

of 54.25 µm and 112.45 µm respectively (figure 12). These same

formulations when delivered with the standard metered spray pump
measured

Mso

of 105.86 µm for 0.5% w /w methylcellulose of 11.35 cps and a

Mgo of 382.38±45.82 µm. Thus nasal micron spray pump was able to reduce

the average droplet size distribution for high viscosity solutions significantly.
However the spray profile for the NMSP showed a bimodal curve which
seems to be due to a portion of spray striking the mouthpiece upon release
from the air blast nozzle. Interestestingly the NMSP delivered the 76 cps
solution formulation as a fine spray, but could not disperse solutions having
higher viscosity than 76 cps as a fine spray. Neverthless thos prototype spray
device seems to have the potential of provideing more "narrowed " spray
distribution for high viscosity formulations .
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FIGURE 12

THE INFLUENCE OF VISCOSITY ON THE DROPLET SIZE DISTRIBUTION
USING NASAL MICRON SPRAY PUMP
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The influence of formulation variables and devices on nasal drug delivery

(

has been focus of many investigations. However there is no published
information on how the different components of nasal spray pump can affect
the spray characteristics and the droplet size. In this study an attempt was
made to determine the influen ce of nasal administration device v ariables,
such as design mechanism of the pumps, actuator, spray insert diameter as
well as the various formulation parameters such as viscosity and presence of
absorption enhancer on the droplet size parameters Mso and M9o. However
the influence of these spray profile on bioavailability is not known and is yet
to be elucidated.
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MANUSCRIPT II
THE INFLUENCE OF TONICITY AND VISCOSITY ON THE INTRANASAL
BIOAV AILABILITY OF SALMON CALCITONIN IN RABBITS.

(
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ABSTRACT
(

As with any drug delivery system, a clear understanding of the
physicochemical and formulation factors is necessary for rational design of
the dosage form. Formulation factors require careful assessment to identify
those which may influence pharmacological or physiological response and
thus assure optimum therapeutic activity. On the basis of physicochemical
and biopharmaceutical studies of peptide or protein drugs; a nasal
formulation administered with an appropriate delivery device may be
designed to provide optimal nasal activity. In the present study an attempt
was made to investigate the effect of tonicity and viscosity on the intranasal
absorption of salmon calcitonin (sCT). Formulations were designed as nasal
sprays with a viscosity of 1 or 76 cps, using 0% w /w and 1% w /w
methylcellulose as the viscosity enhancing agent; and with a tonicity of 100,
300 or 600 mOsms, using sodium chloride as the tonicity adjusting agent to
provide hypotonic, isotonic and hypertonic formulations . Chlorbutanol was
used as a preservative. The low viscosity formulations were delivered using a
metered nasal spray pump and the high viscosity formulations were
administered using a prototype device, the nasal micron spray pump, to
facilitate a uniform distribution of the spray into the nasal cavity. Serum
levels of sCT were determined in healthy male New Zealand rabbits after
intranasal administration of 2000 IU of sCT in 200 µl. The pharmacodynamic
effect of salmon calcitonin of lowering blood calcium level was determined by
a visible spectrophotometric technique. A full factorial design was employed
with ANOVA and Scheffe's multiple comparison test used to analyze the
data. Deviation from isotonicity was found to increase the bioavailability by 4(

5 times . Variation in the viscosity did not influence the bioavailability of
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salmon calcitonin. Response surface methodology and the canonical analysis

(

parameters were applied to determine the optimum formulations.

Key Words: Calcitonin, Intranasal, Tonicity, Viscosity, Methylcellulose, Nasal
spray, Osteoporosis, Spray pumps.

(
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INmODUCTION

The recent phenomenal advancement in biotechnology ha s contrived
stimulating opportunities for the use of peptides and proteins as novel
therapeutic agents. The emergence of these peptides and proteins has raised
questions as to the extent to which existing formulation and drug delivery
technologies can be used and

the type of new technologies that must be

developed to ensure the maximum therapeutic activity. Peptides and proteins
have been administered intravenously beca use of the low oral bioavailability.
This is very inconvenient for patients suffering from chronic diseases.
Therefore, the administration of peptides and proteins by way of the mucosal
routes such as nasal, rectal, buccal, vaginal and ocular mucosae are being
investigatedl .

The use of the intranasal route for systemic delivery of peptide and protein
drugs has several potential advantages including the large surface area of the
nasal cavity and the highly vascularized nature of nasal mucosa. Nasal
absorption of polypeptides such as oxytocin2, synthetic lysine vasopressin3,
synthetic LH-RH and its analogues4, insulinS-7, enkephalins analogs8,
growth hormone releasing factor9-10 has been reported. The permeability of
the nasal mucosa to peptides seems to decrease with increasing molecular
weight. For pep tides with a molecular weight of more than lOOOD,
bioavailabilities are in the range of 1-3%11-12. The nasal absorption efficiency
of peptides and proteins is also influenced by the overall design of the dosage
form as well as the devices used for administration. Some of the dosage forms
which have been investigated are solutions13-14 gelslS, powders16 and

(

microspheres17. These dosage forms have been used for the administration of
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insulinlS-20, human growth hormone21-22, oxytocin23, desmopressin24 and

(

propranolol25. The earliest and the most classical form of nasal formulation
is the solution. However solutions have often been shown to provide lower
bioavailability because they are more readily cleared from the nasal cavity,
particularly when administered as drops. Conversely sprays are confined to
the nonciliated regions of the nasal cavity and therefore are retained longer
than drops26. There is little information on how the formulation variables of
a nasal spray such as buffer concentration, buffer species, ionization of buffer
species, ionic strength, viscosity, charge, pH of vehicle, osmolarity, type and
concentration of preservatives could further influence the absorption of
peptide and proteins.

Salmon Calcitonin, a polypeptide hormone secreted by the parafollicular C
cells of the thyroid gland, lowers serum calcium levels by decreasing bone
and renal tubular reabsorption of calcium. Injectable formulations of salmon
calcitonin have been used with some success in the management of metabolic
bone disorders such as osteoporosis and Paget's disease but this form of
administration is inconvenient and has been poorly tolerated by the patients.
The development of an intranasal preparation of salmon cakitonin will
provide a more convenient means of administering the drug27. Intranasal
spray preparations conta_ining salmon calcitonin have been shown to be
effective in metabolic bone disease28 . Unfortunately nasal bioavailability is
significantly lower than that realized by injection. Salmon calcitonin in a
spray form is now registered in some European countries, however a nasal
spray of salmon calcitonin has not been approved in United States by FDA as
yet. The available data indicate a reasonable absorption, but there is very little
detail addressing the effects of formulation parameters, such as pH, ionization
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of buffer salts, osmolarity, viscosity, etc., on the bioavailability29 -30. To

(

optimize drug activity, the factors influe ncing the drug, for mul ation
components in combination with delivery devices must be identified and
modified to realize significant drug activity.

Since the stability of calcitonin dictates such parameters as pH, buffer and
preservatives; this study was designed to investigate the effect of the
formulation variables, viscosity and tonicity, on the intranasal bioavailability
of salmon calcitonin. Previous studies have been carried out with various
drugs to evaluate the effects resulting from an increase in viscosity in a
formulation. An increase in viscosity is postulated to increase the particle size
of a spray formul ation which leads to a more localized deposition and slower
cleara nce from nose . However, the effects of increased viscosity on
mucociliary clearance, are difficult to interpret. According to some authors, an
increase in viscosity results in a decrease in the clearance rate31. 41 other cases
a progressive increase in viscosity leads to an initial slowdown of clearance
followed by an increase32. Increasing viscosity also seems to progressively
lower the rate of diffusion· of the drug from the deposited droplets resulting
in delayed release and absorption without improvement in bioavailability.
While the above data was generated using viscosity in the range of 1-11 cps,
the present study will investigate the use of a significantly higher viscosity (75 cps) formulation obtained by using 1 % w /w methylcellulose. Previous
studies have shown that metered nasal spray pumps are limited in their
ability to spray higher viscosity solutions as a fine spray. It has been shown
that at is not possible to achieve a gaussian droplet size distribution for
solutions of viscosity greater than 2.12 cps33. However high viscosity

(

for~ulations

can be delivered as a fine spray using a prototype device, the
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nasal micron spray pump, to facilitate the uniform distribution of spray in the
nasal cavity. These results will be compared to those obtained using a low
viscosity formulation, 1 cps, delivered from a commercially available metered
dose spray pump. Additionally, the study will compare the droplet size
distribution obtained with the two different devices, the effect on Tmax, the
time required to obtain maximum concentration in the blood, and the
bioavailability of salmon calcitonin.

Isotonic solutions are used to assist cells in maintaining a stable physiological
environment. Deviation from isotonic conditions can cause tissue damage,
irritation, hemolysis of blood cells and electrolyte imbalance. However very
little information has been generated on the effect of varying the degree of
tonicity for oral or mucosal drug delivery especially intrari.asal formulations.
Absorption of quinine from the small intestine was found to decrease with

(

increasing hypertonicity34 . Malone et al, 1960, reported that the oral
absorption of phenobarbitone in the rat was higher from hypotonic than from
hypertonic solutions35 . However Ohwaki et al, 198436, demonstrated an
increase in the bioavailability of secretin from the nasal cavity with
hypertonicity. Based on the information obtained from these few
experiments, it is difficult to interpret the effect of tonicity on the absorption
in the nasal cavity. The literature does not cite any reference of the effect of
tonicity on the bioavailability of salmon calcitonin. This study investigates
the effect of tonicity at three lev els, isotonicity (300 mOsm), hypotonicity (100
mOsm) and hypertonicity (600 mOsm). These formulations were obtained by
using sodium chloride as tonicity adjusting agent. Since the formulation is
meant for a chronic use, mild deviations from isotonic conditions was
investigated as severe deviation can effect the integrity of the nasal mucosa.

(
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EXPERIMENTAL

(

Materials
Salmon calcitonin (sp. activity 5384 I.U./mg) was a gift from Armour
Pharmaceuticals, Kankanee, IL). RIA Kits were procured from (Diagnostics
Systems laboratories, Webster, TX), Acetic acid and sodium acetate, analytical
grade were purchased from (Fisher Scientific, Fair Lawn, NJ). The anesthetics,
acepopromazine maleate, ketamine hydrochloride (Aveco Co. Inc., Fort
Dodge, IA), DMA Calcium P lus Reagent® (DMA, Houston, TX),
Methylcellulose, Methocel A15C (Dow Chemical Company, Midland, Ml),
Chlorbutanol (Sigma Chemical Company, St. Louis, MO ), Catheters and
Serum separators (Ba xter Health Care Corporation, Deerfield, IL), Heparin
Sodium injection, USP (Elkins-Sinn Inc., Cherry Hill, NJ) were purchased and
used as received. Distilled water was used in all nasal formulations .

(

A 50 µl metered nasal spray pump was chosen to deliver the low viscosity
formulations (1 cps). A prototype device, the nasal micron spray pump
(NMSP), capable of spraying 35 µl per actuation was employed to deliver
formulations of higher viscosity (76 cps). Both the pumps were provided by
Pfeiffer GMBH, Radolfzell, Germany.

Methods
Preparations of formulations
The formulations were prepared with a concentration of methylcellulose
ranging from 0% to 1% w /win a 0.03 M sodium acetate-acetic acid buffer at pH
4 and kept in the refrigerator. A pH of 4 was selected for the formulation as
salmon calcitonin has maximum stability between pH 3-5. The formulation

(
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was refrigerated as salmon calcitonin has been reported to be most stable when
(

stored at 2-40C.

Measurement of the osmotic pressure (tonicity)
The osmotic pressure of the formulati ons was measured using a A-010
Microdiagnostics Osmometer. Standards were measured ranging from 100
mOsm-2000 mOsm and then formulations were measured in duplicate.

Administration of nasal formulations to the rabbits
It has been shown37 tha t differences in volume, concentration, or dosing

technique for an intranasal drug can provide a significant difference in
bioavailability. Instilling a drug as a smaller volume in both nostrils as
compared to a larger volume in one nostril demonstrated a lower coefficent of
variation and slower clearance from the nose.

(
It has been demonstrated38 that the addition of a viscosity enhancing agent

increases the contact time of the dosage form to the mucosa! membrane and
may help to enhance the absorption by reducing the clearance of the
administered drug. Viscosity also changes the pattern of deposition and
clearance38. In these studies the viscosity used was in the range of 1-3.5 cps,
which can be considered as low viscosity solutions. The NMSP, a prototype
device originally developed for inhalation solution was investigated for its
ability to deliver higher viscosity solutions as a fine spray. The lower droplet
size distrib ution for the high viscosity solutions is achieved by the NMSP
using an air blast nozzle as an actuator." By improving the geometry and
therefore the dynamic properties within the spray nozzle, the droplet

(

spectrum has been reduced to smaller diameters leaving the spray nozzle39.
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A standard metered manual spray pump was chosen to deliver low viscosity
formulations (1 cps). A metered 50 µI nasal spray pump based on a ball and
spring mechanism was combined with a flanged actuator using a spray insert
with a 35° spray angle was used. The total volume of 200 µl to contain the
dose was instilled by spraying twice into each nostril. The NMSP was
employed to deliver formulations of higher viscosity (76 cps). The volume
delivered was 35 µl per actuation and a 210 µl volume to contain the dose was
instilled by spraying 3 times into each nostril.

In vivo study
Animal Model
The New Zealand white rabbit was selected as an animal model because it
provides a well controlled animal model for screening the nasal absorption
potential of sprayed drug formulations. The blood volume of the rabbit is

r

sufficiently large to permit frequent blood samples and allow a full
characterization of the absorption profile of the drug40. Rabbits were obtained
from Milbrook farms (Amherst, MA) with a mean weight of about 3 kg. The
study protocol was reviewed and approved by the Institutional Animal Care
and Use Committee, University of Rhode Island, Kingston, RI

Experimental procedure
The rabbits were fasted for 36 hours prior to each experiment with free access
to water. The rabbits were anesthetized with an i.m. dose of 0.25 mg/kg of
ketamine hydrochloride and 2.5 mg/kg of acepopromazine maleate. Rabbits
were kept lying on their backs on thermal rugs during each experiment. A
catheter was placed in the rabbit's median ear artery and a 0.8-1 ml blood
sample was collected at -5, 10, 20, 30, 40, 50, 60, 75, 90, 120, 180, 240 and 300
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minutes after administration of the formulation. The samples were allowed
to clot for at least 30 minutes at room temperature and then centrifuged at
3000 rpm for 10 minutes and stored at

-2ooc until assayed .

The control group was used to measure any interference from the trauma of
administration of anesthesia on the inherent calcitonin level. The control
rabbits were subjected to the same conditions, however calcitonin was not
administered. The values obtained were subtracted from the levels obtained
after administration of calcitonin formulations.

Study Design
Calcitonin was administered as spray to the rabbits as per a randomized cross over design. A wash out period of at least one week was allowed between
treatments .

Analytical methods
Serum calcitonin
All serum samples were assayed with a commercial RIA kit developed at
Diagnostics Systems Labortories (Webster, TX). Guinea pig anti-sCT antibodies
were used as primary antibodies and have demonstrated less than 2% w /w
cross reactivity. The sigmoidal standard curve of B/Bo vs [sCT], typical of
competitive binding assays was linearized using the log transformation. The
best fit line was determined using a non weighted least square regression
analysis. The radioimmunoassay quantitation range was 100-5000 pg/ml. The
square of the coefficent of determination (r2) in this ra nge for the B/Bo versus
log[sCT] plots was greater than 0.993 for all assays performed in duplicate.
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Serum calcium levels

(

Serum calcium levels were determined using a DMA Calcium Plus
Procedure® utilizing arsenazo III to bind the calcium at an acid pH and form
a

bluish

purple

complex.

Ser um

calcium

was

quantified

spectrophotometrically at 650 nm and the range of the linearity was
determined to be between 5-25 mg/ dl. The square of the correlation (r2) in this
range for the absorbance versus concentration (mg/ dl) was 0.999 for all the
assays performed in duplicate during the course of study.

Data Analysis
The concentration of calcitonin was measured in the serum over a period of 5
hours after administration · of salmon calcitonin formulations. Salmon
calcitonin activity was determined as a function of lowering of calcium levels.
The nasal bioavailability of calcitonin was calculated relative to the serum
calcitonin levels over a period of 5 hours after injecting calcitonin
intravenously. Cmax values are the peak serum calcitonin concentrations
observed at time Tmax after adminstration of calcitonin.

%Absolute Bioavailability

=

AUCin-AUCcontrol x Doseiv x 100
AUCiv-AUCcontrol Dosein

The hypocalcemic effect was measured in terms of maximal decrease (%maxd)
which was calculated as the highest percentage of reduction in calcium levels
as compared to the basal values. The total decrease in serum calcium level
(D%) was calculated using a modified method, by Hirai et al, 198141.
D%

=

AUCcontrol-AUCin X JOO
AUCcontrol
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where AUCin, AUCcontrol and AUCiv refer to the area under the curve

(

calculated by the linear trapezoidal rule. AUCin refers to area under the curve
calculated after the intranasal administration of calcitonin formulations.
A UC iv refers to area under the curve calculated after the intravenous
administration of cakitonin formulations. AUCcontrol refers to area under the
curve calculated without administration of the cakitonin. The time at which
this reduction takes place is Tmax.

The data was analyzed by ANOVA using Statistical Analytical Software (SAS).
The formulation effects were compared with the controls using Dunnett's
test. Multiple comparison among the treatment effects were determined
using Fisher's Least Significant Difference test (LSD) and/ or Scheffe's
multiple comparison test. Differences among the treatments were assumed
to be significant for values of p < 0.05.
(

Determination of optimum formulations
One of the main objectives of this investigation was to study the effects of
tonicity and viscosity on the intranasal bioavailability. Tonicity was
investigated at 3 levels of 100, 300 and 600 mOsm and viscosity was studied at
two levels of 1 and 76 cps. In order to optimize the effects of the independent
variables of viscosity and tonicity on the dependent factor, area under the
curve, a full factorial statistical design, was used. A factorial design was used
to study the primary effects of viscosity and tonicity and the secondary effects
or interactions of viscosity and tonicity on the intranasal absorption of sCT

In the simplest of cases, techniques used for optimization involve the
determination of maximum or minima but when the relationship for the
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response is given as a function of two or more than two independent
variables, the system becomes more complicated . In the prese nt case,
Response surface methodology (RSM) was applied to estimate the maximum
or minimum response so as to determine the optimum formulations for the
nasal delivery of salmon calcitonin. The SAS/RSREG software was used to fit
the parameters of the complete quadratic reponse surface obtained from the
three levels of tonicity incorporated in the formulations. The fitted surface
was analyzed to determine the level of the independent variable providing
the optimum response. The predicted optimal value can be found from the
estimated surface, which usually shows a minima, maxima or saddle point, if
there is no clear maxima or minima. Since the independent variable should
be at three or more levels, tonicity was designated an independent variable
with area under the curve as a response surface. Viscosity was used as a
covariate that was investigated at two levels.42
(

RES ULTS AND DISCUSSION

(A) Intravenous administration
The average serum sCT concentration versus time profile for 5 l.U. of i.v.
administered dose is shown in figure 1. The average Cmax was 25±2.9 ng/ml
at a Tmax of 14±2.4 minutes and the area under the curve (AUC) was
1102.1±19.8 ng.min/ml as compared to control group in which average
concentration was 2 ng/ml and the AUC was 401±75.3 ng.min/ml. The
salmon calcitonin levels obtained in the serum were significantly different
from the control level at p< 0.05. The pharmacokinetic parameters are
simmarized in Table I.
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FIGURE 1 CONCENTRATION TIME PROFILE O F SALMON
CALCITONIN AFTER IV ADMINISTRATION (N=5); DOS E 5 IU

40

-

,......

I

! 30il
0
,......
~

<
'1
~

~
~

D

C'ON'lROL

0

Ml:AN

ioi 1

zi;.J

u
z
o·
u

10

()

0

100

200
TIME(MIN)

300

400

,,--...,

..
TABLE I

PHARMACOKINETIC PARAMETERS AFTER INTRANASAL ADMINISTRATION
OF SALMON CALCITQNIN TO NEW ZEALAND RABBITS (N = 5)

VARIABLE

Tmax (min)

Cmax(nglml)

AUC(ng.min/ml)

CONTROL
I.V (5 I.U.)

% Bioavailability

401 ± 75.3
14

25 ± 2.9

1102.1 ± 19.8a

100

ISOTONIC

40

10 ± 4.2

714.2 ± 15.7

0.16

HYPERTONIC

90

42±19.6

3508±1280b

0.80

HYPOTONIC

38

26 ± 7.6

3171±25sb

0.71

ISOTONIC

58

12 ± 9.7

604.6 ± 97.74

0.1 4

HYPERTONIC

90

32±19.6

2183 ± 258b

0.62

HYPOTONIC

120

23±2.4

3579±1030b

0.81

INTRANASAL
LOW VISCOSITY

'1

(,I)

DOSE 2000 I.U.
...l.

INTRANASAL

HIGH VIS~QSII~
DOSE 2000 I.U.

a significantly different from control at p<0.05
b significantly different at low and high viscosity at p<0.5

The pharmacodynamic effect of sCT of low ering calcium is shown in figure 2
and summarized in Table II. The total reduction in calci um level is termed as
D%. The hypocalcemic effect is also

~eas u red

in terms of maximal percent

decrease (%maxd)· which is the highest percent of reduction in calcium levels
as compared to the basal values. The time at which this reduction takes place
is Tmax. However between D% an d %maxd; the 0 % is considered to be a
more acceptable measure of hypocalcemic activity as it encompasses the
overall reduction in activity rather than reduction at one ti me point.

It can be seen that the administration of the 5 IU iv dose resulted in a initial

percent

maxim~l

d ecrease (%maxd) of 28% of calcium at 30 minutes (Tmax) ·

After 30 minutes there w as an increase in the calcium level, and then there
was a grad ual decrease after 75 m inutes until 240 minutes. This pattern of
concentration change may be explained on the basis that often administration
of salmon calcitonin, there is a decrease in the calcium level, once the
calcium lev el reaches a critical value, the parathyroid hormone already
present in the body counteracts the effects of calcitonin and raises the calcium
level. Thus the total lowering, 0 %, was calculated and was found to be 32% as
compared to the control group. The AUC for i.v . administration was
2732±271.39 mg.min/ dL as compared to the AUC for the control group of
4045.40±255.17 mg.min/dL and was significantly different at p<0.05.
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TABLE II

PHARMACODYNAMIC PARAMETERS AFTER INTRANASAL ADMINISTRATION
OF SALMON CALCITONIN TO NEW ZEALAND RABBITS (N =5); DOSE 2000 IU

VARIABLE

Tmax{min}

•

Mil.Q.1%1

AUC {mg.min/g1}

%0

4045.40 ± 255.1 7

CONTROL
30

28

2732 ± 271.39a

32

ISOTONIC

240

12.96

3724.12± 120.99

7.9

HYPERTONIC

75

28.83

3267.74 ± 31.31 a, b

19

HYPOTONIC

180

28.12

3308.0 ± 42.45a

18

ISOTONIC

240

28.81

3242.83 ± 21.66

19

HYPERTONIC

90

23.52

3696.28 ± 53.24a, b

9.0

HYPOTONIC

120

34.58

3154.47 ± 102.49a

22

I.V (5 IU)
LQW VISCQSITY

"en

HigH VISCOSITY

a= significantly different from control at p<0.05
b =signi ficantly different at low and high viscosity p< 0.05

'

----

-...

FIGURE 2 THE INFLUENCE OF IV ADMINISTRATION OF
SA LMON CALCITONIN ON THE CA LCIUM LE VEL (N=S)
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(B) Intranasal administration

(
Effect of tonicity with varying viscosity
Influence of isotonicity

To determine the effect of tonicity on the absorption of salmon calcitonin, the
base formulations containing a dose of 2000 IU salmon calcitonin in a isotonic
0.03 M acetate buffer at a pH 4 with a viscosity of 1 cps were administered to
the rabbits. The AUC, Cmax, Tmax and bioavailability of all the formulations
differing in tonicity are su mmarized in table I. The AUC of isotonic
formulations at a viscosity of lcps w as 714 .2±15.7 ng.min/ml with a
bioavailability of 0.16. The Cmax obtained by the formulations was 10±4.2
ng/ml at a Tmax of 40 minutes.

In contrast higher viscosity (76 cps) isotonic (300m0sm) formulations were
prepared with 1 % methylcellulose at pH 4 containing 2000 IU salmon
calcitonin in 200 µl sprayed into the nasal cavity of rabbits elicited a Cmax of
12±9.7 ng/ml at a Tmax of 58±8.3 minutes as shown in figure 3. The AUC for
the higher viscosity isoton·ic formulations was 604.6±97.74 ng.min/ml with a
bioavailability of 0.14. There was no significant difference in the low and high
viscosity formulations at isotonic conditions.

The bioavailabili ty obtained by the intranasal administration of salmon
calcitonin for low and high v iscosity isotonic formulations was extremely low
and is typical of higher molecular weight polypeptides as shown by previous
investigatorsll.
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FIGURE 3 THE INFLUENCE OF VISCOSITY ON THE
INTRANASAL ABSORPTION OF SALMON CALCJTONJN
IN ISOTONIC SOLUTIONS
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Influence of hypertonicity

(

The low viscosity hypertonic (600m0sm) formulations sprayed intranasally
showed a Cmax of 42±19.6 ng/ml at Tmax of 90±12 minutes as shown in
figure 4, as compared to a Cmax of 10±4.2 ng/ml at a Tmax of 40 minutes for
low viscosity isotonic (300m0sm) formulations . Thus deviation from
isotonicity elicited a higher concentration of sCT in the serum at a low
viscosity of 1 cps. The AUC calculated for low viscosity hypertonic salmon
calcitonin formulations was 3508±1280 ng.min/ml with a bioavailability of
0.80. The bioavailability obtained was about five times higher than that
obtained for low viscosity isotonic formulations .

The higher viscosity (76 cps) hypertonic (600m0sm) formulations prepared
with 1% methylcellulose and sprayed into the nasal cavity of rabbits elicited a
Cmax of 32±19.6 ng/ml at Tmax at 90±12 minutes as shown in figure 4. The
area under the curve was 2183± 258 ng.min/ml with a bioavailability of 0.62.
Thus deviation from isotonicity at a higher viscosity also demonstrated an
increased level of salmon calcitonin in the serum. The bioavailability
obtained by high viscosity hypertonic salmon cakitonin formulations was
significantly different from high viscosity isotonic formulations as
determined at p<0.05

Influence of hypotonicity
The low viscosity (lcps) hypotonic (100m0sm) formulations in an acetate
buffer at pH 4 when sprayed into the nasal cavity of rabbits produced a Cmax
of 26±7.6 ng/ml at Tmax of 38±9.16 minutes as shown in figure 5. The AUC
obtained was 3171.33±258 ng.min/ml with a bioavailability of 0.71. The AUC
obtained for low viscosity hypotonic formulations was almost of the same
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FIGURE 4 THE INFLUENCE OF VISCOSITY ON TH E
INTRANASAL ADSORPTI ON OF SALMON CALCITONJN
IN HYPERTONIC SOLUT IONS
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FIGURE 5 TllE INFLUENCE OF VISCOSITY ON THE
INTRANASAL ABSORPTION OF SALMON CA LC ITO NI N
FOR HYPOTONIC SOLUTlONS
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magnitude as low viscosity hypertonic formulations and was significantly
(

different from low viscosity isotonic formulations at p<0.05.

The higher viscosity hypotonic (lOOmOsm) for mulations prepared with 1%
methylcellulose at a pH of 4 when sp rayed into the nasal cavity of rabbits
produced a Cmax of 23±2.4 ng/ml at Tmax of 120±18 minutes respectively.
The AUC calculated was 3579±1030 ng/ml with a bioavailability of 0.81. Even
at high viscosity, a de viation from isotonicity produced an increase in the
bioavailability.

Thus, it can be seen that absorption of hypertonic and hypotonic formulations
was significantly different from isotonic formulations at both low and high
viscosity and bioavailability of the drug was enhanced in both the hypotonic
and hypertonic conditions by approximately 4-5 fold .

There have been very few experiments performed to study the effect of
tonicity, but the information generated from these studies indicates that
deviation from the tonidty influences the absorption and this could be
explained by the fact that the hypertonic solutions cause shrinkage of the cells
and hypotonic solutions cause swelling of the epithelial cells as a result of
increased water uptake which could alter the pore size within the cell
junctions and the permeability of the cell walls thus leading to enhanced
absorption43.

Influence of viscosity
It can be seen from the literature that low and high viscosity (1-11 cps)

formulations when administered using a metered nasal spray pump that the
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ability of this pump to produce a fine uniform spray is limited for high
viscosity formulations. Therefore, in this study a metered dose spra y pump
based on a ball and spring mechanism was used to spray low viscosity (lcps)
formula tions and a nasal micron spray pump (NMSP) designed with a air
blast spray nozzle was used to spray higher viscosity (76 cps) formulations.
The droplet size d istribution generated by both the devices had been
previously measured using a Malvern sizer and categorized as

Mso which is

the droplet size of 50% of the droplets sprayed33.

The average

Mso

droplet size for formulations with a viscosity of 1 cps was

45±1.llµm and the droplet size

Mso

of formulations of viscosity, 76 cps was

112.48±27.6 µm when sprayed using a metered dose spray pump33. The M50
generated by the NMSP was 53.27±3.38 µm for the 1 cps and 112.45±27.6 µm
for the 76 cps formulations. The M50 generated by two nasal delivery devices
for the formulations differing in viscosity by 76 cps was approximately
different by 2.5 fold (45 µm vs 112.45 µm) . Thus nasal micron spray pump was
very successful in lowering the average droplet size as well as reducing the
range of the droplet size distribution. Interestingly, the distribution produced
by metered nasal spray pump for 1 cps viscosity was Gaussian and unimodal
while that produced by NMSP deviated slightly from Gaussian behavior and
was bimodal33.

The Tma x prod uced b y the low viscosity isotoni c and hypertonic
formulations was 40 and 38 minutes respectively as compared to that for the
higher viscosity isotonic and hypertonic formulations of 58 and 120 minutes
which agrees with literature that postulates that a higher droplet size leads to
a more localized deposition and causes a slower clearance from the nose32.
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However for the hypertonic formulations, the Tmax for both low viscosity
(

and high viscosity formulations was 90 minutes. A possible explanation may
be that the Tmax is not only a measure of higher viscosity but also is affected
b

the other excipients of the formulatio n, especially the tonicity adjusting

agent, sodium chloride which could change the time required to achieve the
maximum concentration by altering the physiological and pharmacological
response generated by the formulation in the surrounding enviornment.

There was a decrease in the absorption of sCT from higher viscosity isotonic
and hypertonic formulations. Similiar results have been reported by Harris,
198932 who used methylcellulose as a viscosity enhancing agent and
demonstrated no improvement in the bioavailability of the drug and actually
reported a decrease in absorption possibly due to the delayed diffusion of drug
from the formulation because of the higher viscosity. Variation in the
viscosity did not show any significant difference in the absorption of sCT.

Pharmacodynamic effects ·
Effect of tonicity with varying viscosity

Influence of Isotoncity
The pharmacodynamic effect of sCT of the lowering of calcium for all the
formulations varying in tonicity as a func tion of viscosity were calculated and
are summarized in table II and shown in figures 6-8. The AUC for isotonic
formulations at low viscosity was found to be 3724.12±120.99 mg.min/dL as
compared to 4045±255.17 mg.min/dL for the control group and 2732±271.39
mg.min/ dL for i.v administration. Isotonic low viscosity formulations
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FIGURE 6 THE INFLUENCE OF VISCOSITY ON THE
CALCIUM LEVEL AFTER INTRANASAL ADMINISTRATION
OF ISOTONIC SALMON CALCITONIN SOLUTIONS
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sprayed intranasally were able to produce a red uction in calcium activity (D%)

(

of 7.9% and a maximum reduction, (%m axd), of 12.96 at a Tmax of 240
minutes. However the low viscosity isotonic formulations were not able to
produce a significant difference as compared to the control group at p<0.05.

The AUC for the high viscosity isotonic formulations was 3242.83±21.66
mg.min/ dL and produced a total reduction in activity of 19% and a
maximum re duction of 28.81 at a Tmax of 240 minutes. There was an initial
maximal decrease at 60 minutes and the level of calcium started rising from
60 minutes until 90 minutes and again there was a gradual decrease until 240
minutes. The maximal percent decrease for the low and high viscosity
isotonic formulations wa s obtained at 240 minutes as seen in figure 6.The
high viscosity isotonic formulations generated a significant difference as
compared to the control and low viscosity isotonic formulations. This may be

(

due to the slower clearance that is postulated for higher viscosity
formulations have longer contact with the mucosa! membrane. The calcium
lowering effect for high viscosity isotonic formulations was significantly
different from low viscosity isotonic formulations and control group.

Influence of hypertonicity
The AUC for the low viscosity hypertonic formulations was 3267.74±31.31
mg.min/ dL as compared 4045±255.17 mg.min/ dL for the control group. These
hypertonic formulations at low viscosity when sprayed intranasally were able
to produce a total reduction in calcium activity (D%) of 19% and a maximl1m
reduction, %maxd, of 28.83 at

a Tmax

of 75 minutes. The total calcium

lowering effect of low viscosity hypertonic formulations was almost 2.5 times

(
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FIGURE 7 THE INFLUENCE OF VISCOSITY ON THE
CALCIUM LEVEL AFTER lNTRANASAL ADMINISTRATION
OF SALMON CALCITONIN llYPERTONIC SOLUTIONS
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more than low viscosity isotonic formulations and was also significantly

(

different from control group.

The AUC for high viscosity hypertonic for m ulations was 3696.28±53.24
m g. m in /dl. and w hen sprayed in tranasally w ere able to produce a total
reduction attivity of 9% and a maximum reduction of 23.52 at a Tmax of 90
minutes . The calcium low ering effect for high viscosity formulations was
significantly different from low viscosity formulations and was more
comparable to the low viscosity isotonic formulations . The difference in the
pattern of low and high v iscosity hypertonic formulations on the calcium
lowering effect is not known.

Influence of hypotonicity
The AUC for the low viscosity hypotonic formulations was 3308±42.45
(

mg.min/ dL and produced a total reduction in calcium activity of 18% and a
maximum reduction of 28.12% at a Tmax of 180 minutes as seen in figure 8..
The calcium lowering effect produced by low viscosity hypotonic
formulations was comparable to that produced by low viscosity hypertonic
formulations and was significantly different from controls.

The AUC for high viscosity hypotonic formulations was 3154.47±102.49
mg.min/dL produced a total reduction in activity of 22% and a maximum
reduction of 34.58 at a Tmax of 120 minutes. The calciu m lowering effect of
the high viscosity hypotonic formulations was also similiar to low viscosity
hypotonic formulations and significantly different from the low viscosity
isotonic and control formulations.
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FIGURE 8 THE INFLUENCE OF VISCOSITY ON THE CALCIUM
LEVEL AFTER INTRANASAL ADMINISTRATION OF SALMON
CALCITONJN HYPOTONIC SOLUTIONS
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The %maxd of 28.83% produced by low viscosity hypertonic formulations (600

(

mOsm) and 28.12% produced by low viscosity hypotonic formulations (100
m Osm) was comparable to 0/..)maxd produced by i.v. administration of 28%.
However the total reduction in activity (O'X.) for the iv formulations were
significantly greater than that seen after nasal administration.

The lowering of calcium for all formulations ranged from 7.9 to 22% of the
basal value in intranasal formulations as compared to 32% for the iv
solutions . The %maxd intranasal delivery ranged from 12 to 34.5% as
compared to 28% in iv administration. The similarity of the extent of the
hypocalcemic effect observed after administration of different intranasal
formulations of sCT may be attributed to the acute homeostatic mechanism
between cakitonin and the parathyroid hormone. The parathyroid hormone
counteracts the effects of calcitonin once a critical level of hypocakemia is
attained. Thus the extent of the hypocalcemic effect is controlled by the
hormonal balance. The acute control of blood calcium is accomplished by the
feedback action of calcitonin and the parathyroid hormone. This complex
regulation of blood calcium concentration makes it difficult to evaluate the
efficacy of sCT delivery systems by observation of the hypocakemic effect44.

Although the measure of pharmacodynamic effects is useful clinically
especially in the event of low bioavailability, the results obtained from the
various biochemical markers for salmon ca lei tonin such as lowering in
calcium, bone turnover and decrease in the urinary hydroxyproline are
difficult to interpret as these parameters are also under hormonal regulation
and may or may not differ for healthy subjects and diseased subjects.
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It has been demonstrated that the h ypocalcemic effect of intranasal salmon

(

calcitonin is governed by the underlying rate of bone turnover and therefore
the effect is minimal in healthy volunteers. That is healthy subjects do not
show a significant change in bone turnover w hile a more pronounced action
is observed in subjects with active osteoporosis or Paget's d isease45.

On the other hand , q uantitative ly simili ar reductions in urinary
hydroxyproline excretion were demons trated, indicating similiar levels of
inhibition of osteoclastic bone resorption following intranasal administration
of 200 to 400 IU salmon calci tonin in he althy volunteers aged less than 30
years and elderly patients w ith osteoporosis or Paget's disease46.

Since the hypocalcemic effects of calcitonin are governed by the underlying
rate of bone turnover, the pharmacokinetic parameters which relate to the

(

presence of salmon calcitonin in the serum should be a more reliable
indicator of the nasal bioavailability of salmon calcition

Optimization of formulations
Six formulations resulting from using 3 levels of tonicity and 2 levels of
viscosity were administered to rabbits. The area under the curve was
calculated and analyzed by ANOVA. The results generated from the
experimental data suggested that h ypertonic and hypotonic formulations
w ere significantly different from isotonic formulations at both low and high
viscosity. The results were confirmed using Scheffe's multiple comparison
test. Regression was carried out to define the relationship between area under
the curve and the independent factors of tonicity and viscosity; and the
optimum region

wa~

determined by the response surface analysis.
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A saddle point curve (figure 9) was obtained which suggests that there is no
maximum or minimum tonicity but that a deviation from the mid point
(isotonicity) would favor an increase in the area under the curve and
ultimately bioav ailability. Viscosity, used as a covariate and plotted along
with tonicity and area under the curve demonstrated that there was no
influence of viscosity on the area under the curve and subsequently
bioavailability. This lack of increasing viscosity effect is shown in figure 9
which indicates a AUC of 8000-10000 ng.min/ml for hypotonic formulations
through out the viscosity range from 1 to 80 cps. There is a decrease in the
AUC from 8000 to 2000 ng.min/ml as the tonicity increases to 300 mOsm.
Again the surface shows a increase as the tonicity increases from 300m0sm to
600 mOsm there is a consistent increase in AUC from 2000-6000 ng.min/ml.

In conclusion it is feasible to enhance the absorption of sCT across the nasal
(

mucosa using proper formulation variables. In spite of low plasma levels and
bioavailability, there are clinical data which support the efficacy of intranasal
formulations in conditions such as Paget's disease and osteoporosis. Clinical
trials have consistently reported an excellent tolerability and acceptability of
intranasal formulationsll.

However further investigations are required for the evaluation of the
toxicological effects of tonicity on the integrity of nasal mucosa, the chronic
use of these formulations when administered intranasally may have the
potential of damaging either the mucociliary system or the underlying
epithelium.
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FIGURE 9 THREE DIMENSIONAL SURFACE PLOT OF TONICITY AND
VISCOSITY VERSUS AREA UNDER THE CURVE

AREA UNDER CURVE
AUC
(ng.min/ml)

-----------------------. --

m1 9000-10000
:;:;:;J 8000-9000

9000

m7000-sooo

8000

R'Kl 6000-7000

7000
6000

[ .J 5000-6000

5000
4000

li:H 4000-5000

10000

co
~

u
;:::::>
~

~.:·:>')

3000

600

2000
1000 ·
O

500
400

r--·-·0

r------20

I

40

Viscosity (cps)

300
200

--··r -

100

60
80

'

II 2000-3000

> ),-....
......
,...

·u c:

Cf)

·c: 0
o

~

,. . . l 3000-4000

E

..._,

!DJ

1000-2000

LJ 0-1000

In summary, the development and use of salmon calcitonin nasal spray holds

(

a lot of promise for the future treatment and management of metabolic bone
disorders.
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MANUSCRIPT III
THE INFLUENCE OF DIMYRISTOYLPHOSPHA TIDYLGLYCEROL ON
THE NASAL ABSORPTION OF SALMON CALCITONIN

(
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ABSTRACT

(
The objective of this investigation was to study the effect of the phospholipid,
dimyristoylphosphatidylglycerol (DMPG) on the intranasal absorption of
polypeptide, salmon calcitonin (sCT). DMPG was included as an absorption
enhancer for salmon calcitonin in a 0.03 M acetate buffer at pH 4 in a nasal
spray formulation. The absorption of sCT was also studied as a function of
NaCl salt concentration from 0.045-0.3 M. Serum calcitonin was determined
using a double antibody RIA. The presence of the phospholipid demonstrated
a significant difference in the intranasal bioavailability of salmon calcitonin.
The results showed DMPG enhanced nasal absorption of sCT by
approximately two fold at a salt concentration of 0.045 M. However higher salt
concentration in the formulations demonstrated a decrease in the absorption
enhancing effect of DMPG. The effect of DMPG on the calcium lowering effect

(

of sCT was also studied. The serum calcium was quantified using arsenazo ID
complex spectrophotometrically at 650 nm. There was no significant
difference in the hypocalcemic activity of sCT in the presence of DMPG. In
addition it was found that increasing viscosity of nasal formulations
containing DMPG could not further increase the bioavailability of sCT.

Key Words: Calcitonin, Dimyristoylphosphatidylglycerol, Absorption

enhancer, Bioavailability, Viscosity, Salt concentration, Nasal micron spray
pump.
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INlRODUCTION

(

The mammalian body possesses several mechanisms to restrict the entry of
macromolecules including polypeptides and proteins. These include the
presence of various epithelia that are poorly absorptive, the presence of
significant levels of enzymatic activity at various locations between the point
of entry into the systemic circulation and the target site of a peptide or
protein, the availability of multiple enzymes to degrade peptides and proteins
at a given location, and varying levels of immunoglobulins to neutralize
peptides and proteins both before and after they are absorbed. The inevitable
outcome is that the bioavailability of peptides and proteins is likely to be
much less than that for a small molecule.

To improve and optimize absorption of peptide and proteins, certain
approaches and strategies have been used and these include, the use of
penetration enhancers to alter membrane permeability, coadministration of
inhibitors to restrain the activity of proteolytic enzymes primarily at the
absorption site, and the use of analogs that are metabolically stable and which
in turn may be more bioavailable.

Among the strategies mentioned, the formulation of macromolecules with
enhancer seems to be a realistic and viable alternative and has been a subject
of many investigations. Penetration enhancers are compounds, generally of
low molecular weight, that facilitate the absorption of solutes across biological
membranes. With few exceptions and regardless of the nonparenteral route
of administration, penetration enhancers are required for the absorption of
peptides and proteins in pharmacologically active quantities.

(
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Most of the penetration enhancers chosen for mucosal delivery have

(

belonged to one of the four major classes. They are: chelators such as EDTA,
citric acid, salicylates, N-acyl derivatives of collagen, and enamine(N-amino
acyl derivatives of 15-diketones); surfactants such as sodium lauryl sulfate,
polyoxyethylene-9-lauryl ether, polyoxyethylene-20-cetyl ether; bile salts such
as sodium deoxycholate, sodium glycocholate, and sodium taurocholate; and

fatty acids such as oleic acid and monoleinl.

·Numerous absorption enhancers have been described for the use in the nasal
route and their efficacy is very evident, although variable, depending on the
peptide considered. Some of these absorption promoters include anionic and
cationic surfactants2, bile salt-fatty acid mixed micelles3, fusidic acid
derivatives4-6, medium chain fatty acid salts7, fatty acid derivatives of
carnitines8, enamine derivatives of amino acids9-10, glycerine estersll,

(

salicylates12-13 and carboxylic acids14 .

Different mechanisms of action have been proposed such as alteration in the
mucus rheology, reduction in the nasal ciliary beat frequency, enhancement
of transcellular transport by affecting membrane lipids and proteins,
enhancement of paracellular transport, suppression of proteolytic activity or
enhancement of the thermodynamic activity of peptides and proteins.
Penetration enhancers improve peptide and protein absorption by one or
more of the several mechanisms. Bile salts have been shown to reduce the
viscosity of the mucus layer adhering to all mucosal surfaces, thereby
facilitating peptide and protein diffusion towards the membrane surfacelS.
Chelators16-19 and to certain extent, polyoxyethylated nonionic surfactants20
interfere with the ability of calcium ions to maintain the dimension of the
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intercellular space, thereby permitting the paracellular transport of peptides

(

and proteins which otherwise will be excluded from this pathway.
Interestingly, most of the penetration enhancers are capable of increasing
membrane fluidity either by creating disorder in the phospholipid domain in
the membrane, as is the case of salicylates, oleic acid and monolein21-23, or by
facilitating the leaching of proteins from the membrane, as in the case for
surfactants and EDTA.

The efficiency of penetration enhancers depends on several factors, including
the nature of peptides, the physicochemical properties of the delivery system
as related to peptide and protein release, lipophilicity of the enhancer, the
intrinsic ability of the enhancer to perturb membrane permeability, the site of
application of enhancer and the animal species used.

(

Nature of peptide: The intrinsic ability of peptides to cross biological
membranes is anticipated to be a complex function of their physicochemical
properties. The bioavailability of peptide following nasal administration
varies with their primary structure, although the precise relationship
between absorption and physicochemical properties is as yet unknown. The
coadministration of peptides with . 1% sodium glycocholate elicited an
increase in the absorption of a poorly absorbable peptide, namely leuprolide,
However it had no effect on the absorption of metkephamid, which is
relatively well absorbed peptide. Interestingly even in the presence of
adjuvants, the bioavailability of leuprolide and insulin was far from
complete24-26.

Del_ivery systems: The selection of a delivery system for a peptide and its

106

penetration enhancer must take into account the vast difference in

(

physicochemical properties that may exist between these two substances due
to the difference in their release rates from the system. For a penetration
enhancer to be effective, it must be released either simultaneously with the
peptide or shortly before the peptide itself is released. This requirement is
supported by the findings of Nishhata et al27 in that the bioavailability of
insulin following rectal adminstration in the rat was reduced from 30.2% to
12.8% when the release of DL-phenylalanyl ethylacetoacetate, the adjuvant,
from the suppository was delayed from 17.5 to 30 minutes prior to the
administration of insulin.

Nature of enhancer: A penetration enhancer must be able to penetrate the
membrane and at the same time, achieve a high enough comcentration to
perturb membrane structure28. Hirai et al29 determined that somewhat

(

lipophilic ester and ether type nonionic surfactants with HLB values of 10-14
appeared to optimize the nasal absorption of insulin in the rat when
compared with extremely hydrophilic or lipophilic derivatives. The
coadministration of monolein and bile salts has been found to bring about a
synergistic effect in enhancing the oral absorption of heparin in the rat
persumably due to the facilitation of the membrane penetration of the bile
salt by monolein30. Inspite of its attractiveness in optimizing the efficiency of
adjuvants, the approach of using co-adjuvants that operate by different
mechanisms has not been fully explored.

Potency of enhancer: In a series of phenylalanylenamine type enhancers,
which act by chealting Ca2+, the extent of hypoglycemia in rabbits following
rectal administration of insulin was most pronounced for the most potent

(
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chelators in that series31.

Site of administration: Because the permeability characteristics of each
mucosal site vary, the extent of absorption of a peptide differs depending on
the site of administration32. Polyoxyethylene-9-lauryl ether and sodium
glycocholate were far more effective in promoting the nasal absorption of
leuprolide rather than vaginal absorption18. This was not a surprising
finding in light of the fact that the nasal epithelium is comprised of columar
cells whereas the vaginal epithelium is comprised of stratified squamous
cells33.

Animal model: The animal model that reliably mimics peptides and protein
absorption in humans, both in the presence and absence of penetration
enhancers, has yet to be established. Preliminary evidence suggests that, at
least in the case of the nasal absorption of insulin, the extent of enhancement
may be a function of the animal model chosen34-35.

Since absorption enhancers promote peptide and protein absorption by
perturbing membrane integrity, it is inevitable that a varying extent of
damage would occur to these mucosal tissues which are in intimate contact
with an enhancer. To date only few studies have been undertaken to
determine the nature of the potentially exaggerated effects or toxicities caused
by the various types of penetration enhancers36-38. Overall non-surfactant
type enhancers when used on an acute basis appear to cause less severe and
more readily reversible morphological changes than their surfactants
counterparts. Aside from morphological changes, there is virtually no
information on the biochemical changes that may occur locally or the
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systemic toxicity which may result from the absorption of the penetration
enhancers themselves and from the absorption of toxins at the mucosal
surfaces that otherwise would be excluded from the systemic circulation.
Membrane damaging effects have been demonstrated by protein release39,
ciliostasis40, and histological examinations41. Such toxicity may eventually
preclude use of these agents in clinical trials.

Another emerging class of absorption enhancers is phospholipids. They
occurs in cell membranes and can be classifed as acidic or zwitter ions.
Lysophospholipids are surface active zwitter ion compounds generated
naturally in biological membranes by action of phospholipases. They are
active in low concentrations and are converted within the membrane to
normal cell components42. L-a-Lysophosphatidykholine (LPC) has been
shown to increase the permeability of rat ileum to macromolecules43 and has
more recently been investigated as an enhancer for the intranasal absorption
of insulin in rats44 and of human growth hormone in rats, rabbits and
sheep45-46 although its histopathological effects on the nasal tissue have not
been reported. The mechanisms of absorption promotion for LPC is poorly
understood but it possesses "membrane activity" and has shown absorption
enhancing properties45. Dimyristoylphosphatidylglycerol (DMPG) is an acidic
phospholipid which has been shown to interact with certain polypeptides like
glucagon, insulin, cakitonin, parathyroid, secretin, and growth hormone to
form an amphipathic helix47. Circular Dichroism spectroscopy studies show
that sCT forms an amphipathic helix and adopts a conformation of higher
helical content in the presence of phospholipid DMPG48. This hydrophilic
lipoprotein complex (DMPG-sCT) has been associated with an increase in the
hypocakemic activity49-50 . However there have been no literature citation of
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describing the use of DMPG as an nasal absorption enhancer for calcitionin.
(

Calcitonin is a 32 amino acid amidated peptide used for over two decades to
treat certain degenerative bone diseases and the hypercalcemia associated
with malignancy. Before 1989, calcitonin was administered exclusively by the
parenteral route. The bioavailability of an intravenous dose is absolute.
However the chronic nature of the ailment and the high cost and discomfort
associated with parenteral administration decreases patient compliance. The
feasibility of the administration of calcitonin via the nasal route has been
documented and the results have been encouraging51.

Nasal spray formulations of salmon calcitonin currently are on the market in
Europe and Japan and have been extremely well received. Similiar approvals
are pending in the United States. These products have provided a much

(

needed alternative for patients, however extremely low bioavailability of less
than 3% of the free drug when administered nasally necessitates the use of
absorption enhancers52.

The objective of this investigation was to study (i) the effect of DMPG on the
intranasal absorption of sCT in the presence of various NaCl salt
concentrations in a range of 0.045-0.3 M (ii) the effect of DMPG on the calcium
lowering effect of sCT (iii) whether the addition of a viscosity enhancer to
these formulations would further increase the intranasal bioavailability of
sCT.

(
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EXPERIMENTAL

(

Materials
Salmon calcitonin (sp. activity 5384 IU /mg) was obtained from Armour
Pharmaceuticals, Kankanee, IL. Dimyristoylphosphatidylglycerol (DMPG) was
purchased from Avanti Lipids, Alabaster, AL. RIA Kits were procured from
Diagnostics Systems laboratories, Webster, TX. Acetic acid and Sodium
acetate, analytical grade were purchased from Fisher Scientific, Fair lawn,

NJ.

Anesthetics acepopromazine maleate, ketamine hydrochloride were
purchased from Aveco Co. Inc., Fort Dodge, IA. DMA Calcium Plus
Reagent®, DMA, Houston, TX, Methylcellulose, Methocel A15C, Dow
Chemical Company, Midland Ml. Chlorbutanol, Sigma Chemical Company,
St. Louis MO, Catheters and Serum separators, Baxter Health Care
Corporation, Deerfield, IL, Heparin Sodium injection, USP, Elkins-Sinn Inc.,
Cherry Hill, NJ were purchased and used as recieved. Distilled water was used

(

for all nasal formulations.

A metered nasal spray pump was used to spray 50 µl at one time. Nasal
micron spray pump was employed to deliver formulations of higher viscosity
(76 cps), methylcellulose 1% w /w. The volume delivered was 35 µl at one
time. Both the pumps were provided by Pfeiffer GMBH, Radolfzell, Germany.

Methods
Preparation of formulations containing DMPG and sCT at low viscosity
(1 cps)
DMPG was added as a solid to a 0.03 M acetate buffer (pH 4) and the mixture
was stirred. Calcitonin was added and it was allowed to interact at room
temperature for 5-6 hrs. The ratio of DMPG to salmon calcitonin was 50:1, this
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particular ratio provided a dose of sCT of 2000 IU and 1% w /w of DMPG. The
(

affinity of sCT for DMPG has been shown to be independent of temperature
within experimental error, between 25 and 38° C and the reaction is very
spontaneous .

Preparation of formulation containing DMPG and sCT at high viscosity
(76 cps)
It has also been demonstrated53 that the addition of a viscosity enhancing

agent increases the contact time of the dosage form with the mucosal
membrane and may help to enhance absorption by reducing the mucociliary
clearance of the administered drug.

To prepare formulations containing DMPG and sCT at a higher viscosity of 76
cps, methylcellulose was used as a viscosity enhancing agent at a
concentration of 1% w /w. The formulations were prepared using a hot-cold
technique. The methykellulose was dispersed in hot water and then ice cold
water was added and stirred for 4-5 hrs for methylcellulose to swell and
hydrate and reach the specified viscosity. The pH was adjusted to 4. DMPG
and calcitonin were added. The mixture was allowed to interact at room
temperature for 5-6 hrs.

Administration of nasal formulations to the rabbits
It has been shown54 that by adjusting the volume and the concentration of

intranasal drug, a significant difference in bioavailability can be obtained. The
bioavailability of desmopressin from 2X50 µl dose was 20% greater than after
administration of a lXlOO µl dose. Instilling the drug as a smaller volume in
both nostrils as compared to larger volume in one nostril demonstrated
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slower clearance from the nose.

(
However the metered nasal sprays are limited 1~ fheif ·afiility to spray only
low viscosity solutions (< 5 cps) as fine spray. The nasal micron spray pump,
a prototype device, designed to deliver solution5 ~of higher viscosity as a fine
spray was investigated for its use in nasal drug d~l!v-ery5~ t ·
. -ii,... -

/_
A metered nasal spray pump based on the meclY~niS-m Of ball and spring with
a flanged actuator using a spray insert of 350: s.pfaY- cfng1~twas used to spray 50
.

,,.-

µl of low vicosity solutions (1 cps) at orie .- till\e).. ,:~hd £Re?i 1fotal volume of the
... ,
dose instilled was 200 µl by spraying 2 time~~Jnto each nostril. The nasal
~

micron spray pump was employed to deliver formulations of higher viscosity
(76 cps). The volume delivered was 35 j.il" cif%rte. ti~ ~Jd a total of 210 µl

dose was instilled by spraying 3 times info'-~atl\~strll. E nh ·

(
In vivo study
Animal Model
New Zealand white rabbits were obtairled -ff.om ;MUb'i'bol< farms (Amherst,
MA) with a mean weight of about 3 k'g. Tne'~Sttuiiy pf-mifcdl was reviewed and
approved by the Institutional Animal Care and Use Committee at the
University of Rhode Island, Kingston, RI

Experimental procedure
The rabbits were fasted for 36 hours prior

to each expe'r iment with free

access

to water. The rabbit~ were anesthetized\~ifth an ·1.m-: 2tlos~ of 0.25 mg/kg of
ketamine hydrochloride and 2.5 mg/kg ~6f· a·clipoprohla~fue maleate. Rabbits
were kept lying on their backs on thermal rugs dtiffng ~ach experiment. A
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catheter was placed in the rabbit's median ear artery and a 0.8-1 ml of blood

(

samples was collected at -5, 10, 20, 30, 40, 50, 60, 75, 90, 120, 180, 240 and 300
minutes after administration of the formulations. The samples w ere allowed
to clot for at least 30 minutes at room temperature and then centrifuged at
3000 rpm for 10 minutes and stored at -200 C until assayed.

For control formulations, rabbits were anesthetized and blood was withdrawn
at the same intervals as mentioned above and serum analyzed. This was
called control group as no calcitonin was administered and was used to
measure any interference from the trauma on administration of anesthesia
on the inherent calcitonin level. The values obtained were subtracted from
the levels obtained after administration of calcitonin formulations .

Study Design

(

The various formulations of calcitonin were administered as spray to the
rabbits as per a randomized cross-over design. A wash out period of at least
one week was allowed between treatments.

Analytical methods
Serum calcitonin
All serum samples were assayed with a commercial RIA kit developed by
Diagnostics Systems Labortories (Webster, TX). Guinea pig anti-sCT antibodies
were used as primary antibodies and have demonstrated less than 2% w /w
cross reactivity. The sigmoidal standard curve of B/Bo versus [sCT], typical of
competitive binding assays was linearized using a log transformation of sCT.
The best fit line was determined using a non weighted least square regression
analysis. The radioimmunoassay quantitation range was 100-5000 pg/ml. The

(
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coefficent of determination (r2) in this range for the B/Bo versus log [sCT]

(

plots was greater than 0.993 for all assays performed in duplicate.

Serum calcium levels
Serum calcium levels were determined using a DMA Calcium Plus
Procedure® utilizing arsenazo III to bind the calcium at an acid pH and
form

a

bluis h

purple

comple x.

Color

intensity

was

measured

spectrophotometrically at 650 nm. The range of the linearity was determined
to be between 5-25 mg/ dl. The coefficient of determination (r2) in this range
for the absorbance versus concentration (mg/ dL) was 0.999 for all the assays
performed in duplicate during the course of study.

Data Analysis
The nasal bioavailability of calcitonin was calculated relative to the serum
cakitonin levels after injecting calcitonin intravenously. Cmax values are the
peak serum calcitonin concentrations observed at time Tmax after
adminstration of calcitonin.
%Absolute Bioavailability = AUCin-AUCcontrol X Doseiv X 100
AUCiv-AUCcontrol Dosein
where AUCin, AUCiv and AUCcontrol refer to the area under the curve
calculated by the linear trapezoidal rule. AUCin refers to area under the curve
calculated after the intranasal administration of calcitonin formulations.
A U Civ refer s to area under the curve calculated after the intravenous
administration of calcitonin formulations. AUCcontrol refers to area under the
curve calculated without administration of cakitonin.
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The hypocalcemic effect was measured in terms of percent maximal decrease

(

(%maxd); which is defined as the highest percentage of reduction in calcium
levels as compared to the basal values. The total decrease in serum calcium
level (D%) was calculated by a modified method, from Hirai et al, 1981.
D% =

AUCcontrol-AUCin X lOO
AUCcontrol

where AUCin, AUCcontrol and AUCiv refer to the area under the curve
calculated by the linear trapezoidal rule after the intranasal administration of
calcitonin formulations. The time at which this reduction takes place is Tmax.
Statistical analysis was performed using ANOVA by Statistical Analytical
Software (SAS). Formulation effects were compared with the controls using
Dunnett's test. Multiple comparison among the treatment effects were
determined using Scheffe's multiple comparison test. Differences among the
treatment were assumed to be significant for values of p < 0.05.

Selection of best formulations
The primary aim of this investigation was to study the effect of DMPG on the
intranasal bioavailability of sCT. The influence of DMPG was investigated at
the three levels of salt concentration of 0.045 M, 0.15 Mand 0.3 M. In order to
optimize the effect of these salt concentrations and the concentration of
DMPG on area under the curve, response surface analysis was applied. The
SAS/RSREG was used to fit the parameters of the complete quadratic reponse
surface obtained at the three levels of salt concentration incorporated in the
formulations and analyze the fitted surface to determine the level of the salt
concentration needed for the optimum form ulations. The predicted optimal
value can be found from the estimated surface, which usually shows a

(

mif1:ima, maxima or saddle point, Since the independent variable should be
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at three or more levels, salt concentration was designated as independent

(

variable with area under the curve as a response surface and the
concentration of DMPG was used as a covariate investigated at two levels.56

RES ULTS A ND DISCUSSION

Currently, two classes of nasally delivered therapeutic compounds are on the
market. The first and largest class encompasses low molecular weight drugs
designed to treat local inflammation of the nasal mucosa and sinuses. This
class includes topical steroids, cromolyn sodium, and most over the counter
nasal products. These compounds are generally hydrophobic in their unionized form, and readily partition into the mucosal membrane. The second
class includes those drugs intended for systemic delivery after intranasal
administration. Despite the attractiveness of the nasal cavity for systemic
administration, the secon d class includes only a few compounds: vasopressin,
oxytocin, LH-RH analogs, calcitonin, and vitamin B-12. Except for vitamin B12, the compounds are all peptides and show very low bioavailability.

Although the bioavailability of these peptides is low, therapeutic activity may
often be sufficient because of the high biological potency of these compounds.

This study was designed to evaluate the phospholipid, DMPG, as an
absorption enhancer and to determine its ability to enhance the
bioavailability of salmon calcitonin. Phospholipids may be directly involved
in the binding of many drugs and hormones to specific cell-surface receptors
sites47-48, There is evidence that binding to lipid is required for the activity of
peptides including enkephalin57 and

thyrotropinSB. Calcitonin is a

membrane active peptide and its interaction with the lipid may be related to
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its biological activity. Circular Dichroism spectroscopy studies show that
(

salmon calcitonin (sCT) forms an amphipathic helix and adopts a
conformation of higher helical content in the presence of the phospholipid,
Dimyristoylphosphatidylglycerol (DMPG). Thi s hydrophili c lipoprotein
complex has been associated with an increase in the hypocalcemic
activity48-50.

Pharmacokinetic studies
Since salts are often used in nasal formul ations to adjust ionic strength,
tonicity etc, it was decided to investigate the effect of salt concentration on the
absorption of sCT with or /without DMPG. Table I summarizes the Tmax,
Cmax, AUC and Bioavailability for the formulations investigated. In order to
determine the absolute bioavailability of intranasal sCT formulations, the
AUC fo r the control formulation and i.v solution was also determined and
was calculated to be 401±75.3 and 1102.1±19.8 ng.min/ml.

Low viscosity formulations
Effect of 0.045 M Na Cl
The influence of DMPG on the absorption of sCT in a formulation containing
0.045 M N aCl at a viscosity of 1 cps is shown in figure 1. The Cmax obtained
for the formulation containing only sCT was 26±7.6 ng/ml at 38 minutes
whereas the Cmax elicited by the formulation containing only DMPG and sCT
increased to 82±30 ng/m l at 90 minutes. The AUC elicited by sCT formulation
at 0.045 M N aCl w as 3171±258 ng.min/ml and an absolute bioavailability of
0.71 whereas the AUC elicited by formulation incorporating DMPG and sCT at
0.045 M NaCl was 6017±706 ng.min/ml with an absolute bioavailability of 1.4.
/

The presence of DMPG and sCT in the formulation demonstrated a two fold
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Figure 1 THE INFLUENCE OF A SALT CONCENTRATION OF
0.045 MAND DMPG ON THE INTRANASAL ABSORPTION
OF SALMON CALCITONIN
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TABLE I PHARMACOKINETIC PARAMETERS OF LOW VISCOSITY SALMON CALCITONIN
FORMULATIONS AFTERINTRANASAL ADMINISTRATION IN NEW
ZEALAND RABBITS (N = 5)
VARIABLE

Tmax (min)

~

Cmax(ng/ml)

CONTROL
J.V (5 I.U.)

AUC(ng.min/ml)

%Bioavailabili~

401±75.3
14

25 ± 2.9

1102.l ± 19.8a

100

o.045 M

38

26 ± 7.6

3171±258b

0.71

O.lSM

40

10 ±4.2

714.2 ± 15.7C

0.16

0.3M

90

42±19.6

3508±1280

0.80

INTRANASAL

§.ct:
DOSE 2000 I.U.

....
~

0

I

INTRANASAL
DMfS:Z-11CT

DOSE 2000 I.U.
0.045M

90

82±30

6017± 706b

1.4

0.15M

10

22 ±30

1521±275c

0.34

O.JM

63

28±7.5

3692± 1369

0.84

a significantly different from control at p<0.05
b significantly different in AUC for DMPG formulations at 0.045 M NaCl at p<0.05
c significantly different in AUC for DMPG formulations at 0.15 M NaCl at p<0.05

increase in the absorption of sCT as compared to formulation containing only
sCT at a NaCl concentration of 0.045 Mand a viscosity of 1 cps.

Effect of 0.15 M NaO
The influence of DMPG on the absorption of sCT

from formulations

prepared w ith 0.15 M NaCl at a viscosity of 1 cps is shown in figure 2. The
Cmax was found to be 10± 4.2 ng/ml at 40 minutes for the formulations
containing only sCT whereas the Cmax increased to 22 ng/ml at 10 minutes
for the formu lations incorporating DMPG and sCT. The AUC elicited was
714 .2 ng.min/ml and an absolute bioavailability of 0.16 for the sCT

formulation as compared to an AUC of

15~1

ng.min/ml and an absolute

bioavailability of 0.34 for the formulations containing DMPG and sCT. These
results demonstrated that even at a NaCl salt concentration of 0.15 M and a
viscosity of 1 cps, the bioavailability elicited by the presence of DMPG in sCT
formulations increased two fold compared to sCT formulations without
DMPG. However the bioavailability elicited by sCT with a 0.045 M NaCl salt
concentration and a viscosity of 1 cps was higher as compared to formulations
containing sCT at a 0.15 M NaCl salt concentration and a viscosity of 1 cps
(1.4% versus 0.34%).

Effect of 0.3 M Na Cl
The influence of increasing the NaCl salt concentration to 0.3 M with a
viscosity of 1 cps in the absence or presence of DMPG on the bioavailability of
sCT is shown in figure 3. The Cm ax was 42±19.6 ng/ml at 90 minutes for the
sCT formulations. The Cmax was reduced to 28±7.5 ng/ml at 63 minutes in
the presence of DMPG in the sCT formulations. The AUC for the sCT
administration was 3508±1280 ng.min/ml with an absolute bioavailability of
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Figure 2 THE INFLUENCE OF A SALT CONCENTRATION OF
0.15 M AND DMPG ON THE INTRANASAL ABSORPTION
OF SALMON CALCITONIN
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Figure 3 THE INFLUENCE OF A SALT CONCENTRATION OF
0.3 M AND DMPG ON THE INTRANASAL ABSORPTION
OF SALMON CALCITONIN
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0.80 as compared to an AUC of 3692±1369 ng.min / ml and an absolute

(

bioavailability of 0.84 in the presence of DMPG in sCT formulations.
Therefore in the presence of higher salt concentration of 0.3 M NaCl, the
absorption of sCT was not affected by the presence of DMPG, in fact it was
approximately the same magnitude as seen w ithout addition of DMPG. This
indicated that DMPG did not have any absorption enhancing effect on sCT
absorption at 0.3 M. Therefore maximum bioavailability elicited by DMPG
and the sCT formulations was obtained at the lowest concentration of NaCL

Pharmacodynamic effects
It has been suggested that the presence of DMPG in an sCT formulation

enhances the helical activity of sCT and may be related to the increase in the
hypocalcemic activity48-SO. Thus the parameters of hypocalcemic activity
were determined for formulations containing only sCT and those containing
DMPG along with sCT. The results are summarized in Table II as Tmax (min),
%maxd (percent maximal decrease), AUC (mg.min/dL) and D% (total
hypocalcemic activity).

Low viscosity formulations
Effect of 0.045 M NaCl
The influence of DMPG on the calcium level after intranasal administration
of sCT in the presence of 0.045 M NaCl at a viscosity of 1 cps is shown in
figure 4. The maximal decrease, %maxd was 28.12% at 180 minutes for sCT
formulations as compared to %maxd of 34.58% at 120 minutes for
formulations incorporating DMPG and sCT. The AUC was 3308±42.45
mg.min/ dL and a total lowering of calcium, D% of 18% for sCT formulations
as compared to a AUC of 3209.55±21.66 mg.min/ dL with D% of 19% in the

124

-----..

TABLE II PHARMACODYNAMIC PARAMETERS OF LOW VISCOSITY SALMON CALCITONIN
FORMULATIONS AFTER INTRANASAL ADMINISTRATION INTO NEW ZEALAND RABBITS
(N =5); DOSE = 2000 I. U.

VARIABLE

Im~~(minl

•

MaxdJ.%1

CONTROL

A:UC (rng.min/dLl

.%..D.

4045.40 ± 255.17
..

30

28

2732 ± 271.39a

32

0. 045M

180

28.12

3308.0 ± 42.45

18

0.15M

240

12.96

3724.12±120.99b

7.9

0.3M

180

28.83

3267.74 ± 31.31

19

0.045M

120

34.58

3209.55 ± 21.66

19

0.15M

so

38.89

2884.70 ± 53,24b

20

0.3M

90

38.49

3208 ± 102.49

20

I.V (5 l.U.)
sCT

....
~

en

QMPG-sCT

a= significantly different from control at p> 0.05
b =significantly different in calcium levels at p> 0.05

,,...--.,
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FIGURE 4 THE INFLUENCE OF A SALT CONCENTRATION
OF 0.045 M AND DMPG ON THE CALCIUM LEVEL AFTER
INTRANASAL ADMINISTRATION OF SALMON CALCITONIN
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sCT formulations incorporating DMPG. Thus for formulations containing

(

0.045 M NaCl salt and a viscosity of 1 cps, the maximal decrease in calcium
elicited by the presence of DMPG and sCT was higher (34.15% versus 28.12%),
but D%, which is the overall measure of the hypocalcernic activity of sCT was
similiar (18% versus 19%) to sCT formulations. Thus there was no significant
difference in the total hypocalcemic activity elicited by formulations with or
without the enhancer at p <0.5.

Effect of 0.15 M NaCl
The influence of DMPG on the calcium level after intranasal administration
of sCT in the presence of 0.15 M NaCl at a viscosity of 1 cps is shown in

figur~

5. The %maxd was 12.96% at 240 minutes and 38.89% at 50 minutes in the
absence and presence of DMPG in the sCT formulations respectively. The
AUC was 3724.12±120.99 mg.min/dL with a total lowering of calcium, D% of
7.9% for sCT formulations as compared to the AUC of 2884.70±53.24
mg.min/ dL with a D% of 20% in the presence of DMPG in sCT formulations.
The comparison of AUC and a D% for these two formulations demonstrated
that there was a significant difference on the total lowering of calcium level
in the presence of DMPG in sCT formulations at a salt concentration of 0.15 M
and a viscosity of 1 cps as compared to sCT formulations (20% vs 7.9%) at
p <0.05.

Effect of 0.3M Nao
The influence of DMPG on the calcium level after intranasal administration
of formulations containing sCT in the presence of 0.3 M NaCl at a viscosity of
1 cps is shown in figure 6. The maximal decrease was 28.83% at 180 minutes
for formulations containing only sCT as compared to 38.49% at 90 minutes for
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FIGURE 5 THE INFLUENCE OF A SALT CONCENTRATION
OF 0.15 M AND DMPG ON THE CALCIUM LEVEL AFTER
INTRANASAL ADMINISTRATION OF SALMON CALCITONIN
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FIGURE 6 THE INFLUENCE OF A SALT CONCENTRATION
OF 0.3 M AND DMPG ON THE CALCIUM LEVEL AFTE R
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formulations incorporating DMPG and sCT. The AUC was 3267.74±31.31

(

mg.min/ dL and a total lowering of calcium, D% of 19% for sCT formulations
as compared to AUC of 3208±102.49

mg.min/ dL with a D% of 20% for

formulations containing DMPG and sCT. This indicated that the total
lowering in calcium was comparable, in the absence and presence of DMPG at
a salt concentration of 0.3 M (19% versus 20%). Therefore the calcium
lowering effects of sCT were demonstrated to be not affected by presence of
DMPG when the salt concentration was 0.3 M.

The hypocalcemic activity was comparable for formulations containing only
sCT and for formulations incorporating DMPG with sCT at a NaCl salt
concentration of 0.045 M and 0.3 M at the low viscosity of 1 cps. However at a
NaCl salt concentration of 0.15 M with a viscosity of 1 cps, the formulations
containing DMPG with sCT showed a significant difference in the calcium

(

lowering effect of salmon calcitonin. However in all the three salt
concentrations the total lowering of calcium ranged from 7.9% to 20%. The
Tmax calculated as a pharmacodynamic parameter for the maximum
lowering of calcium ranged from 50 to 240 minutes indicating the
pharmacodynamic acitivity of salmon calcitonin in lowering of calcium is
sustained and does not correlate with the presence of calcitonin in the serum.

Influence of viscosity
It was hypothesized that higher viscosity formulations may act in synergism

with the absorption enhancing effect of DMPG at a NaCl salt concentration of
0.045-0.3 M. The pharmacokinetic parameters obtained after administering
the absorption enhancer, DMPG in sCT formulations at the higher viscosity
of 76 cps were compared to the low viscosity formulations of 1 cps, with and
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without the DMPG. The study was designed to evaluate the use of high
viscosity (- 75 cps) formulations obtained by using 1% w /w methykellulose
delivered as a fine spray with a prototype device, the nasal micron spray
pump, to facilitate the uniform distribution of spray in the nasal cavity55.

It has been demonstrated53 that the addition of methykellulose produced a

more sustained and slower absorption as indicated by the difference in time to
reach maximum plasma concentrations. However the AUC data indicated a
similiar bioavailability for the two formulations . It is thought that the
addition of a viscosity enhancing agent such as methykellulose increases the
contact time of the dosage form to the mucosal membrane and may help in
enhancing the absorption by reducing the mucociliary clearance of the
administered formulation and also changing the pattern of deposition and
clearance59 An increase in viscosity increases the particle size in a spray
formulation. It also leads to a more localized deposition on the anterior part
of the nose and thus facilitates slower clearance60.

On the other hand, with regard to mucociliary clearance, results are difficult
to interpret. According to some authors, an increase in viscosity results in a
decrease in the clearance rate61. Viscosity also influences the rate of diffusion
of the active ingredient resulting in delayed release without any
improvements in bioavailability62.

The influence of viscosity on formulations containing DMPG as compared to
formulations without DMPG at a NaCl concentration of 0.045-0.3 M are
shown in figure 7-9. The pharmacokinetic parameters of these formulations
are summarized in Table III.
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TABLE III PHARMACOKINETIC PARAMETERS OF HIGH VISCOSITY SALMON CALCITONIN
FORMULATIONS AFTERINTRANASAL ADMINISTRATION IN NEW
ZEALAND RABBITS (N = 5)
VARIABLE

Tmax (min)

~

Cmax(ng/ml)

AUC(ng.min/ml)

CONT ROL
I.V (S l.U.)

%Bioavailability

401±75.3
14

25 ± 2.9

1102.1 ± 19.8a

100

0.045 M

120

23 ± 2.4

3579± 103

0.71

0.15M

58

12 ±9.7

604.64± 97.74b

0.14

0.3M

90

32±19.6

3589± 25c

0.72

INTRAN ASAL
sCT
DOSE 2000 I.U.

....

(.\)
~

'

INTRANASAL
QMfG-~CT

DOS E 2000 I.U.

0.045 M

90

54±24

4203 ±384.1

0.96

O.lSM

10

13 ± 7

1244 ± 275b

0.28

0.3M

63

8±7.5

2134± 1369C

0.56

a significantly different from control at p<0.05
b significantly different in AUC for DMPG formulations at 0.15 M NaCl at p<0.05
c significantly different in AUC for DMPG formulations at 0.3M N aCl at p<0.05

High Viscosity formulation

Effect of 0.045 M NaO
The influence of DMPG on the absorption of sCT in formu lations containing
0.045 M NaCl at a viscosity of 76 cps is shown in figure 7. The Cmax was 23
ng/ml at 120 minutes for the sCT formulations as compared to the Cmax of
54±24 ng/ml at 55 minutes elicited by the presence of DMPG in sCT
formulations. The AUC was 3579±103.0 ng.min/ml in the absence of DMPG
and 4203±706 ng.min/ml in the presence of DMPG with an absolute
bioavailability of 0.81 and 0.96 respectively. The presence of DMPG at a high
viscosity of 76 cps did not make a significant difference in the bioavailability
of sCT at a NaCl concentration of 0.045 M (0.96 vs 0.81). However DMPG at a
low viscosity of 1 cps elicited a two fold increase in the bioavailability (1.4 vs
0.71). This can be explained by the fact that increased viscosity reduces the

(

diffusion of the drug from the formulation to the site of absorption. Thus the
tmax is increased to 60 and 120 minutes for the two high viscosity
formulations as compared to the 38 minutes for the low viscosity
formulations without much improvement in bioavailabity.

Effect of 0.15 M NaO
The effect of the formulation containing DMPG and sCT

at a NaCl

concentration of 0.15 Mat 76 cps is shown in figure 8. The Cmax obtained for
formulations containing only sCT was 12±9.7 ng/ml at 58 minutes as
compared to the Cmax for formulations containing DMPG and sCT of 13±7
ng/ml at 90 minutes . The AUC was 604.64 ng.min/ml and an absolute
bioavailability of 0.14 for sCT formulation whereas an AUC of 1244.914±275.65
ng.min/ml and a bioavailability of 0.28 was obtained for the formulations
containing DMPG and sCT. At NaCl salt concentration of 0.15 M, there was a
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Figure 7 THE INFLUENCE OF A SALT CONCENTRATION OF
0.045 M AND DMPG ON THE INT RANASAL ABSORPTION
OF SALMON CALCITONIN AT HIGH VISCOSI TY
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Figure 8 THE INFLUENCE OF A SALT CONCENTRATION OF
0.15 M AND DMPG ON THE INTRANASAL ABSORPTION
OF SALMON CALCITONIN AT HIGH VISCOSITY
25
0

z

0

I

20

~

~

~~-

....
(,.)
(11

ze

()

0

T.

15

-

~Oli

CONTROL
sCT
sCT&DMPG

u-.S

z

0

10

u
5 ..JI _j l~,/(d. I/

\I

\

T

o--~~~~~~_.....___...'--~~~~~~~~~~~~

0

100

200

TIME( MIN)

300

400

two fold increase (0.28 vs 0.14) in the bioavailability of sCT in the presence of
{

DMPG at a high viscosity of 76 cps . These results were very similiar to those
obtained at low viscosity formulations of 1 cps at a salt concentration of 0.15
M.

Effect of 0.3 M NaO
The effect of the formulation containing DMPG and sCT at a NaCl
concentration of 0.3 M and 76 cps is shown in figure 9. The Cmax was 32±19.6
ng/ml at 90 minutes for the salmon calcitonin formulations. The Cmax was
8±7.5 ng/ml at 63 minutes for DMPG and sCT formulations . The absolute
bioavailability of 0.72 was obtained for sCT formulations in the presence of 0.3
M salt as compared to a bioavailability of 0.56 for formulations containing
DMPG and sCT in the presence of 0.3 M as shown inTable III. This
demonstrated that in the presence of higher salt concentration of 0.3 M NaCl
the DMPG did not elicit an absorption enhancing effect. These results
correlated with results obtained for low viscosity formulations at 0.3 M NaCl
salt concentration.

Pharmacodynamic effects
High viscosity formulations
The parameters for the hypocalcemic activity of the high viscosity
formulations with and without DMPG are summarized in Table IV as
Tmax(min), %maxd (maximal percent decrease), AUC (mg.min/ dL) and D%
(total hypocalcemic activity). A review of the pharmacodynamic effect of sCT
of lowering of calcium is illustrated in figures 10-12.

f
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Figure 9 THE INFLUENCE OF A SALT CONCENTRATION OF
0.3 M AND DMPG ON THE INTRANASAL ADSORPTION
OF SALMON CALCITONIN
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TABLE IV PHARMACODYNAMIC PARAMETERS OF HIGH VISCOSITY SALMON CALCITONIN
FORMULATIONS AFTER INTRANASAL ADMINISTRATION INTO NEW ZEALAND
RABBITS (N =5); DOSE = 2000 I. U.

YARIABLE

"loMaxd

Tmax(min)

AUC (mg.min/dl)
4045.40 ± 255.17

CONTROL
I.V (5 I.U.)

%D

30

..

28

2732 ± 271.39a

32

INTRANASAL

&I
DOSE 2000 I.U.

...
CQ

Q)

0.045M

120

34.58

3154.47

22

0.15M

240

28.81

3242.83b

19

0.3M

90

23.52

0.045M

90

28.36

3331

17

0.15M

180

27.09

3161.67

21

0.3M

75

29.01

3510.80

13

' 3696.28

. 9

INTRANASAL
DM~Q&~CT

DOSE 2000 I.U.

a significantly different from control at p<0.05
b significantly different in AUC for DMPG formulations at 0.15 Mat p<0.5

Effect of 0.045 M NaO
(

The influence of DMPG on the calcium level after intranasal administration
of sCT in the presence of 0.045 M NaCl and at a viscosity of 76 cps is shown in
figure 10. The maximal decrease was 34.58% at 300 minutes and 28.36% at 90
minutes in the absence and presence of DMPG respectively. A total lowering
of calcium of 22% for formulations containing sCT whereas a D% of 17% for
formulations incorporating DMPG in sCT was obtained. There was no
significant difference on the calcium level in the absence or presence of
DMPG at 0.045M NaCl at a viscosity of 76 cps.

Effect of 0.15 M NaO
The influence of DMPG on the calcium level after intranasal administration
of sCT in the presence of 0.15 M NaCl and at a viscosity of 76 cps is shown in
figure 11. The %maxd was 28.81 % at 240 minutes and 27.09% at 180 minutes
in the absence and presence of DMPG respectively. The AUC was 3242.83
mg.min/ dL with a D% of 19% for formulations containing sCT and 3161.679
mg.min/dL with D% of 21% for formulations containing DMPG and sCT. The
comparison of AUC and a· D% of these two formulations demonstrated that
there was no significant difference in the calcium level by high viscosity
formulations at a salt concentration of 0.15 M containing enhancer or without
enhancer. These results were different from those obtained at a low viscosity
of 1 cps where there was a significant difference in the overall hypocalcemic
activity of formulations with and without enhancer. The reason for this
difference is not known.

Effect of 0.3 M NaO
The influence of DMPG on the calcium level after intranasal administration
\
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FIGURE 10 THE INFLUENCE OF A SALT CONCENTRATION
OF 0.045 M AND DMPG ON THE CALCIUM LEVEL AFTER
INTRANASAL ADMINISTRATION OF SALMON CALCITONIN AT
HIGH VISCOSITY
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FIGURE 11 THE INFLUENCE OF A SALT CONCENTRATION
OF 0.15 M AND DMPG ON THE CALCIUM LEVEL AFTER
INTRANASAL ADMINISTRATION OF SALMON CALC ITONIN
AT HIGH VISCOSITY
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FIGURE 12 THE INFLUENCE OF A SALT CONCENTRATION
OF 0.3 M AND DMPG ON THE CALCIUM LEVEL AFTER
INTRANASAL ADMINISTRATION OF SALMON CALCITONIN
AT HIGH VISCOSITY
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of sCT in the presence of 0.3 M NaCl and a viscosity of 76 cps is shown in

(

figure 12. The %maxd was 23.52% at 90 minutes and 29.01 % at 75 minutes in
the absence and presence of DMPG respectively. The AUC was 3696.28
mg.min/ dL with a D% of 9% was calculated for formulations containing only
sCT as compared to the AUC of 3510.801 mg.min/ dL with a D% of 13%
obtained by formulations containing containing DMPG and sCT. Again there
was no significant difference in the total calcium lowering effect of sCT in the
absence and presence of DMPG (9% vs 13% ).

The similarity in the extent of the hypocalcemic effect observed for the
different formulations of sCT especially those which demonstrated significant
differences in absorption of sCT may be attributed to the acute homeostatic
mechanism between calcitonin and parathyroid hormone. The parathyroid
hormone counteracts the effects of calcitonin once a critical level of
hypocalcemia is attained . Thus the extent of the hypocalcemic effect is
controlled by the hormonal balance. The acute control of blood calcium is
accomplished by the feedback action of calcitonin and parathyroid
hormone63. This complex regulation of blood calcium concentration makes it
difficult to evaluate the efficacy of sCT delivery systems by observation of the
hypocalcemic effect. Additionally the short half life of sCT makes it more
difficult to correlate serum sCT and its biological effects64.

Selection of the best formulations
Response surface methodology was used as a optimization technique to select
the levels of the variables

that could best describe the most desirable

attributes of the formulation. The response surface analysis plot
demonstrated that a maxima was obtained, which suggests that there is a
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Figure 13 THREE DIMENSIONAL SURFACE PLOT SHOWING
MAXIMA FOR DMPG AND SALT CONCENTRATION WITH
RESPECT TO AREA UNDER THE CURVE
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optimum salt concentration to deliver DMPG. The three dimensional plot

(

included concentration of NaCl on X-axis, concentration of DMPG on Y-axis
and AUC on Z-axis. Figure 13 indicates an AUC of 25000-30000 ng.min/ml for
0.045M formulations with DMPG at a concentration of 2% and a AUC of 050000 ng.min/ml for formulations with a NaCl of concentration > 0.25M and
a DMPG of 0-0.5% w /w concentration. Thus the analysis suggests that the
most effective formulation should contain DMPG at a salt concentration of
0.045M to provide the best absorption enhancing effect of DMPG on salmon
ca lei tonin.

To overcome the low bioavailability of higher molecular weight polypeptides
in intranasal delivery, it becomes necessary to include an absorption
enhancer. However the choice of absorption enhancer is very important as it
should be able to increase the uptake of the peptide, at the same time it
should be safe, nontoxic in long term use and should not alter the physiology,
histology of nasal cavity. This study not only investigated the role of DMPG
in enhancing the absorption but also the effect of other formulation factors
such as viscosity and salt concentration on the efficacy of this enhancer. Very
little work has been done on phospholipids as absorption enhancers,
especially acidic absorption enhancers. It is extremely important to study their
effects after chronic use on ciliary beat freqency, histology and physiological
functions before they can be approved as an excipient in the formulations
meant for nasal delivery.
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CONCLUSIONS
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(

1.

A study of delivery devices and components which used the Malvern
laser sizer to determine the qualitative and quantitative spray profile
indicated that the currently available metered nasal devices were capable
of dispensing low viscosity solutions as a fine spray and maintaining a
Gaussian distribution. The devices also demonstrated an excellent total
dose delivery and reproducibility for all types of solutions.

2.

The nasal micron spray pump, a prototype device, that was developed
for pulmonary drug delivery is very versatile and can be extremely
valuable in nasal drug delivery. It is capable of generating a
narrower droplet size distribution and a fine spray for viscous
solutions which cannot be achieved with currently available spray
pumps.

(

3.

Among the formulation variables investigated, tonicity elicited a
significant difference in achieving a higher concentration of salmon
calcitonin in the serum and enhancing the bioavailability of salmon
ca lei tonin.

4.

Viscosity studied at the two levels indicated that although the droplet
spray distribution was significantly affected, no significant improvement
in the bioavailability of salmon calcitonin was found for solutions
differing in viscosity.
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5.

(

The use of dimyristoylphosphatidylglycerol, an acidic phospholipid, a
novel permeation enhancer demonstrated an increase in the
bioavailability of salmon calcitonin.

6.

The absorption enhancing activity of dimyristoylphosphatidylglycerol
when studied as a function of salt concentration indicated that a low salt
concentration was required for the optimal activity.

7.

The pharmacodynamic effect of salmon calcitonin of lowering of
calcium indicated that although it was a useful parameter for indirectly
measuring the efficacy of salmon calcitonin formulations, it did not
correlate directly with the plasma concentration of the drug and was very
difficult to interpret the results. This inconsistency was attributed to the
fact that the hypocalcemic response is controlled by the parathyroid gland

(

which correctively responds to cakitonin plasma concentration.

8.

The low bioavailability of higher molecular weight polypeptides such as
salmon calcitonin can be enhanced by a optimization of both
formulation parameters and nasal administration device variables.

This investigation emphasized a need to study both formulation and
devices variables to overcome low bioavailability. This approach is of
tremendous value to the formulation scientist by increasing the
probability of optimizing drug delivery and accelerating product
development.
\
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SECTION III

(

(
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APPENDIX A
TECHNIQUES USED FOR ANALYSIS
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QUANTITATIVE DETERMINA ITION OF SALMON CALCITONIN IN
SERUM
Double Antibody Radioimmunoassay

Principle
Double antibody radioimmunoassay is a sequential competitve
radioimmunoassay. The sample is first preincubated with anti- calcitonin
serum. 125_1 -labeled calcitonin then competes with the calcitonin in the
serum samples for antibody sites. After incubation for a fixed time, separation
of bound from free is achieved by the PEG- acclerated double antibody
method. The antibody-bound fraction is precipitated by centrifugation under
refrigerated conditions. The precipitated pellets are counted by a gamma
counter.
(

Reagents provided (Diagnostics Systems Limited, Webster, TX)
1. Calcitonin Antiserum contains guinea pig as primary antibodies.

2. 125 I- Calcitonin
3. 125 I- Calcitonin calibrators.
Six vials labeled A through E with 0 to 50 ng/ml concentration of
salmon calcitonin.
4. Precipitating reagent
One vial of precipitating reagent consisting of guinea pig-antigoat
gamma globulin in polyethlene glycol.
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5. Calcitonin controls
(

Two vials labeled calcitonin controls I and II containing calcitonin in a
protein based matrix containing 2 mg/ ml and 10 ng/ml as low and
high control levels of salmon calcitonin.

All the samples except precipitating reagent were lyophilized. They were
stored in refrigerator and were reconstituted with distilled water for 30
minutes before the use.

Procedure
Serum samples were incubated with calcitonin antiserum for 6 hrs at 2-80C.
After the first incubation, radiolabeled calcitonin was added and samples
reincubated for 24 hrs at 2-80C. Separation was achieved by the addition of
precipitating reagent and was followed by a third incubation for 1 hr. THe

(

samples were centrifuged for 30 minutes aat 3000 rpm at 2oC. The
supernatant was drained off, the rim of tubes wiped to eliminate radioactive
contamination and precipitated pellets were counted in a gamma counter for
1 minute in terms of cpm (counts per minute) and analysis of each sample
was performed in duplicate.

Calculations
To be able to calculate the concentration of calcitonin on serum samples, the
first step was to calculate the total count, non-specific binding, maximum
binding and %B/Bo.
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The cpm of 125 Iodinated Calcitonin was counted and termed as total counts.
The nonspecific binding (NSB) was determined by using deionized water
instead of serum samples and was subtracted from the readingt in cpm
obtained for all serum samples,

Net Count= average cpm - average NSB cpm

Maximum binding was provided by zero ng/ml of calcitonin standard. The
counts obtained by Ong/ml and subtracted by non-specific binding was taken
to be 100% and was called maximum binding.
Percent bound (B/Bo) =Net count
Net maximum binding

X 100

The sigmoidal standard curve of B/Bo vs log[sCT], typical of competitive

(

binding assays was linearized using the log transformation. Using th.e linear
log graph paper, percent bound was plotted on the vertical axis against
concentration on the horizontal axis for each of the nonzero calibrators. The
best fit was determined using a non weighted least square regression analysis.

Results
The radioirnrnunoassay quantitation range was 100 pg/ml- 5000 pg/ml. The
square of the coefficient of determination on this range for the B/Bo versus
log[sCT] plots was greater than 0.993 for all assays performed in duplicate.
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QUANTITATIVE DETERMINATION OF CALCIUM IN SERUM
CALCIUM PLUS® PROCEDURE

Principle
The calcium plus® procedure developed by DMA, Houston, TX., utilizes a
dye, arsenazo III which binds to calcium at an acid pH. A bluish - purple
complex is formed. The intensity of the color formed is measured by an
increase in absorbance of the reaction mixture at 650 nm.

Reagents Provided
Calcium plus® reagent
Control sera of concentration of calcium 10 mg/ dL

(

Composition of Calcium Plus Reagent
Arsenzo ill (0.136 mmol/L)
Buffer
Surfactant
Sodium azide

Manual Procedure
1. Add 2 ml of calcium plus reagent into labeled test tubes.
2. Add 0.025 ml of each control and samples to their respective test tubes.

3. Mix well
4. Use 0.025 ml deionized water for reagent blank instead of sample or control.
5. Incubate for 2 minutes at the reaction temperature.

(
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6. Set the wavelength of the instrument at 650 nm. Zero with the reagent

(

blank.
7. Read and record absorbance of the samples and controls.

Calculations

Absorbance of unknown
Absorbance of standard

X Concentration of standard

= Calcium (mg/dL)

RESULTS

Serum calcium was quantified by uv spectroscopy and the range of the
linearity was determined to be between 5 mg/ dL - 25 mg/ dL. The square of the
coefficient of determination in this range for the absorbance (AUFS) versus
concentration (mg/ dL) was 0.999 for all the assays performed in duplicate
during the course of study.
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STANDARD CURVE OF CALCIUM USING
ARSENAZO COMPLEX III MEASURED AT 650 nm.
0.8
0.7

00 0.6
~

;;;;i

< 0.5
..._,

...
O>
Q)

~

u 0.4

z

<

~ 0.3
0
~ 0.2

<
0.1

r 2 = 0.999

y = 0.038x - 0.040

0.0
5

10

15
CONCENTRATION (mg/di)

20

25

(

APPENDIX

B

STATISTICAL DATA SUPPORTING MANUSCRIPT
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I

STATISTICAL ANALYSIS OF MALVERN DATA
FORMULATION VARIABLE - VISCOSITY

Analysis of Variance Procedure
Dependent Variable: MSO
Sum of
Squares

Mean
Square

Source

OF

Model

2

6204.0566000

3102.0283000

Error

6

147.0588000

24.5098000

Corrected Total

8

6351.1154000

R-Square
0.976845

C.V.
7.138084

Root MSE
4.9507373

Pr> F

F Value

126.56

0.0001

M50Mean
69.356667

Dependent Variable: M90
Sum of
Squares

Mean
Square

Source

OF

Model

2

90381.751489

45190.875744

Error

6

1183.945667

197.324278

Corrected Total 8

91565.697156

R-Square
0.987070

C.V.
8.366806

RootMSE
14.047216

(
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F Value

229.02

Pr::> F
0.0001

M90 Mean
167.89222

(

STATISTICAL ANALYSIS OF i\IALVERN DATA
FORMULATION VARIAllLE - TONICITY

Analysis of Variance Procedure
Class Level Information
Class

Levels

TON

3

Values

HYE HYO ISO

Number of observations in data set= 9

Dependent Variable: M50
Sum of
Squares

Mean
Square

Source

OF

Model

2

10.10816089

5.05408044

Error

6

12.95668267

2.15944711

Corrected Total 8

23.06484356

Source

OF

TON

2

Anova SS
10.10816089

FValue

Mean Square
5.05408044

2.34

Pr> F
0.1773

F Value
2.34

Pr> F
0.1773

Dependent Variable: M90
Mean
Square

F Value

Pr> F

6821.6386727

3410.8193363

12.02

0.0080

6

1703.2526833

283.87544 72

Corrected Total 8

.8524.8913560

Source

OF

Model

2

Error

Sum of
Squares
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STATISTICAL ANALYSIS OF MALVERN DA TA
FORMULATION VARIABLE - CONCENTRATION OF ENHANCER

Analysis of Variance Procedure
Dependent Variable: MSO
Sum of
Squares

Mean
Square

Source

DF

Model

1

1008.8066667

1008.8066667

Error

4

22 .7437333

5.6859333

Corrected Total 5

0.977952

177.42

Pr> F
0.0002

1031.5504000

c.v.

R-Square

(

F Value

4.097113

RootMSE
2.3845195

M50 Mean
58.200000

Dependent Variable: M90
Sum of
Squares

Source

OF

Model

1

6591.5461500

Error

4

95.5715333

Corrected Total 5
R-Square
0.985708

Mean
Square
6591.5461500

F Value
275.88

Pr> F
0.0001

23.8928833

6687.1176833
C.V.
4.891867

Root MSE
4.8880347
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M90 Mean
99.921667

(

STATISTICAL ANALYSIS OF MALVERN DATA
DEVICE VARIABLE - MECHANISM OF PUMP
Analysis of Variance Procedure
Dependent Variable: MSO
Source

OF

Model

1

Error

Sum of
Squares
13.89281667

4

10.48746667

Corrected Total 5

24.38028333

c.v.

R-Square
0.569838

3.527836

Mean
Square

F Value

13.89281667

5.30

Pr> F
0.0828

2.62186667

Root MSE
1.6192179

M50 Mean
45.898333

Dependent Variable: M90
Sum of
Squares

Mean
Square F Value

Source

OF

Model

1

1341.6130667

1341.6130667

Error

4

2483.1138667

620.7784667

Corrected Total

5

3824.7269333

R-Square
0.350774

c.v.
27.20223

Root MSE
24.915426
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2.16

Pr> F
0.2155

M90Mean
91.593333

(

STATISTICAL ANALYSIS OF MALVERN DATA
DEVICE VARIABLE - SPRAY ANGLE
Analysis of Variance Procedure
Gass Level Information
Gass

Levels

ANGLE

3

Values
600 350 200

Number of observations in data set= 9

Dependent Variable: M50
Sum of
Source
OF
Squares

Mean
Square

Model

2

10.13763200

5.06881600

Error

6

12.42667200

2.07111200

Corrected Total 8

F Value
2.45

Pr> F
0.1670

22.56430400

Source

OF

ANGLE

2

Anova SS
10.13763200

Mean Square F Value
5.06881600

2.45

Pr> F

0.1670

Dependent Variable: M90

DF

Source

Sum of
Squares

Mean
Square F Value

Model

2

3143.8714729

1571.9357364

Error

6

2118.8262373

353.1377062

Corrected Total 8

5262.6977102
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4.45

Pr> F
0.0653

(

STA TISTICAL ANALYSIS OF MAL VERN DA TA
DEVICE VARIABLE - ORIFICE DIAMETER

Analysis of Variance Procedure
Dependent Variable: MSO
Sum of
Squares

Mean
Square F Value

Source

OF

Model

2

10.19342222

5.09671111

Error

6

12.93220000

2.15536667

Corrected Total 8

23.12562222

R-Square

(

0.440785

c.v.
3.198202

Root MSE
1.4681167

2.36

2

5899.8090667

2949. 9045333

Error

6

1764.5765333

294.0960889

Corrected Total

8

7664.3856000

R-Square
0.769769

C.V.
19.42742

Root MSE
17.149230

(
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0.1749

M50 Mean
45.904444

Dependent Variable: M90
Sum of
Mean
Source
OF
Squares
Square F Value
.Model

Pr> F

10.03

Pr> F
0.0122

M90 Mean
88.273333

(

APPENDIX C
STATISTICAL DATA SUPPORTING MANUSCRIPT I & II
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General Linear Models Procedure

Scheffe's test for variable: Y

NOTE: This test controls the type I experimentwise error rate
but generally has a higher type II error rate than REGWF
for all pairwise comparisons

Alpha= 0.05 df= 26 MSE= 8012872
Critical Value of F= 4.22520
Minimum Significant Difference= 1939.5

(

Means with the same letter are not significantly different.

Mean

N

VIS

A

4775.8

18

1

A

2957.8

18

76

Scheffe Grouping
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(

Scheffe's test for variable: Y

NOTE: This test controls the type I experimentwise error rate
but generally has a higher type II error rate than REGWF
for all pairwise comparisons

Alpha= 0.05 df= 26 MSE= 8012872
Critical Value of F= 3.36902
Minimum Significant Difference= 2999.7

(

Means with the same letter are not significantly different.

Scheffe Grouping

A
A
B

B

Mean

N

TON

6319

12

100

3612

12

600

1760

12

300
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(

Gener;il Lineu Models Procedure
Scheffe's test for vari;ible:
NOTE: Thi s test controls the type I experimentwise error rate
but ge ner;ill y h;is

<1

higher type II error rnte than REGWF

for all pairwise comparisons

Alph;i= 0.05 df= 26 MSE= 801287
Critical Value of F= 4.22520
Minimum Significant Difference= 1939.5
Means with the s;ime letter are not signific;intly different.

Scheffe Grouping

A

B
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Mean

N

DMPG

5331.1

18

1.0

2402.6

18

0

(

General Linear Models Procedure

T tests (LSD) for variable: Y

NOTE: This test controls the type I comparisonwise error rate
not the experimentwise error rate.

Alpha= 0.05 df= 26 MSE= 8012872
Critical Value of T= 2.06
Least Significant Difference= 1939.5

Means with the same letter are not significantly different.

T Grouping

Mean

N VIS

A

4775.8

18

1

A

2957.8

18

76
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General Linear Models Procedure

T tests (LSD) for variable: Y

NOTE: This test controls the type I comparison wise error rate
not the experirnentwise error rate.

Alpha= 0.05 df= 26 MSE= 8012872
Critical Value of T= 2.06

(

Least Significant Difference= 2375.4

Means with the same letter are not significantly different.

T Grouping

Mean

N TON

A

6319

12 100

B

3612

12 600

B

1670

12 300
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General Linear Models Procedure

T tests (LSD) for variable: Y

NOTE: This test controls the type I comparison wise error rate
not the experimentwise error rate.

Alpha= 0.05 df= 26 MSE= 8012872
Critical Value of T= 2.06
Least Significant Difference= 1939.5

Means with the same letter are not significantly different.

TGrouping

A

B

(
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Mean

5331.1

2402.6

N DMPG

18 1.0

18 0

(

Source

OF

Type I SS

F Value

Pr> F

VIS

1

29745956.016

3.71

0.0650

DMPG

1

77188149.634

9.63

0.0046

TON

2

130842909.196

8.16

0.0018

DMPG*TON

2

59202705.613

3.69

0.0387

VIS*TON

2

62767100.747

3.92

0.0326

VIS*DMPG

1

888473.395

0.11

0.7418

Dependent Variable: Y

Source

OF

Type II SS

F Value

VIS

1

29745956.016

3.71

0.0650

DMPG

1

77188149.634

9.63

0.0046

TON

2

130842909.196

8.16

0.0018

DMPG*TON

2

59202705.613

3.69

0.0387

VIS*TON

2

62767100.747

3.92

0.0326

VIS*DMPG

1

888473.395

0.11

0.7418
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Pr> F

(

Dependent Variable: Y
Source

OF

Type III SS

F Value

Pr> F

VIS

1

29745956.016

3.71

0.0650

DMPG

1

77188149.634

9.63

0.0046

TON

2

130842909.196

8.16

0.0018

DMPG .. TON

2

59202705.613

3.69

0.038 7

VIS .. TON

2

62767100.747

3.92

0.0326

VIS .. DMPG

1

888473.395

0.11

0.7418

Dependent Variable: Y
Source

OF

Type IV SS

F Value

Pr> F

VIS

1

29745956.016

3.71

0.0650

DMPG

1

77188149.634

9.63

0.0046

TON

2

130842909.196

8.16

0.0018

DMPG,.TON

2

59202705.613

3.69

0.0387

VIS,.TON

2

62767100.747

3.92

0.0326

VIS,.DMPG

1

888473.395

0.11

0.7418
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PROCGLM;
CLASS VIS DMPG TON;
MODEL Y = VIS DMPG TON DMPG*TON TON*VIS VIS*DMPG/SSI SS2 SS3
SS4;
MEANS VIS DMPG TON/SCHEFFE;
MEANS VIS DMPG TON/LSD;
RUN;
PROCRSREG;
MODEL Y =

VIS DMPG TON I PREDICT;

RIDGE MAX;
RUN;
DATA A; DMPG = l;
VIS= -20;
DO I= 1TO5;
TON= O;
VIS = VIS+20;
DOJ= 1 T06;
TON = TON + 100;
Y = 7610.88 -17.01*VIS+13237*DMPG - 39.68.. TON + 16.76*DMPG*VIS
- 0.034*TON*VIS - 24.07*TON*DMPG + 0.058*TON*TON;
OUTPUT;
END;
END;
PROCPRINT;

I

\
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Coding Coefficients for the Independent Variables

Factor

Subtracted off

Divided by

38.500000

37.500000

DMPG

0.250000

0.250000

TON

350.000000

VIS

250.000000

Response Surface for Variable Y

(

Response Mean

3866.841889

Root MSE

3120.984519

R-Square

0.5207

Coef. of Variation

80.7115

Degrees of Type I Sum
Regression

Freedom

of Squares

R-Square

F-Ratio

Prob> F

Linear

3

137385648

0:2415

4.702

0.0088

Quadratic

1

100391366

0.1764

10.307

0.0033

Crossproduct

3

58457705

0.1027

2.000

0.1368

Total Regress

7

296234720

0.5207

4.345

0.0023
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Degrees
of
Parameter

(

Freedom

Parameter

Standard

T for HO:

Estimate

Error

Parameter=O

INTERCEPT

1

7610.872353 2403.668564

VIS

1

-17.017080

DMPG

1

TON

1

-39.680564

VIS*VIS

0

0

DMPG*VIS

1

16.757132

DMPG*DMPG

0

0

29.852014

13237 4503.851317

55.484169

0.302

-0.034236

0.067505

TON*DMPG

1

-24.075277

10.125811

0.059433

0.018513

Parameter Estimate from Coded
Parameter
INTERCEPT

Prob> ITI

Data

0.0037

1250.697729

VIS

0.5732

-930.395314

DMPG

0.0065

TON

0.0083

VIS*VIS
DMPG*VIS
DMPG*DMPG

1363.966125
-1353.585583
0

0.7649

2.939
-2.840

1

1

-0.570

13.970208

TON*VIS

TON*TON

3.166

157.098111
0

187

-0.507
-2.378
3.210

(

Parameter Estimate from Coded

Parameter

Prob> ITI

TON*VIS

0.6160

-320.966371

TON*DMPG

0.0245

-1504.704792

TON*TON

0.0033

Data

3714.566354

Degrees
of
Factor

Freedom

Sum of
Squares

Mean Square

VIS

3

33139861

DMPG

3

133140423

44380141

TON

4

188412141

47103035

11046620

Canonical Analysis of Response Surface
(based on coded data)
Critical Value
Factor

Coded

Uncoded

VIS

47.250043

1810.376607

DMPG

17.853221

TON

5.839590

4.713305
1809.897426

(
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F-Ratio
1.134
4.556
4.836

Prob> F
0.3523
0.0101
0.0043

Coded
Radius

Uncoded Factor Values
VIS

DMPG

TON

0.0

38.500000

0.250000

350.000000

0.1

37.221271

0.263987

331.113469

0.2

36.525396

0.274531

308.467457

0.3

36.167287

0.282944

284.441931

0.4

35. 990575

0.290160

259.959596

0.5

35. 917028

0.296676

235.327136

Coded
Radius

Uncoded Factor Values
VIS

DMPG

TON

0.6

35.906673

0.302752

210.650463

0.7

35.937585

0.308538

185.968059

0.8

35.996872

0.314121

161.293960

0.9

36.076490 .

0.319558

136.632759

1.0

36.171171

0.324886

111.985288
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SIMULATED DATA FOR RESPONSE SURFACE ANALYSIS

TON

J

y

1

100

1

9637.88

0

1

200

2

6206.38

0.5

0

1

300

3

3934.88

4

0.5

0

1

400

4

2823.38

5

0.5

0

1

500

5

2871.88

6

0.5

0

1

600

6

4080.38

7

0.5

20

2

100

1

9397.28

8

0.5

20

2

200

2

5897.78

9

0.5

20

2

300

3

3558.28

10

0.5

20

2

400

4

2378.78

11

0.5

20

2

500

5

2359.28

12

0.5

20

2

600

6

3499.78

13

0.5

40

3

100

1

9156.68

14

0.5

40

3

200

2

5589.18

15

0.5

40

3

300

3

3181.68

16

0.5

40

3

400

4

1934.18

17

0.5

40

3

500

5

1846.68

18

0.5

40

3

600

6

2919.18

19

0.5

60

4

100

1

8916.08

20

0.5

60

4

200

2

5280.58

DMPG

VIS

1

0.5

0

2

0.5

3

OBS
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SIMULATED DATA FOR RESPONSE SURFACE ANALYSIS

f

TON

J

y

4

300

3

2805.08

60

4

400

4

1489.58

0.5

60

4

500

5

1334.08

24

0.5

60

4

600

6

2338.58

25

0.5

80

5

100

1

8675.48

26

0.5

80

5

200

2

4971.98

27

0.5

80

5

300

3

2428.48

28

0.5

80

5

400

4

1044.98

29

0.5

80

5

500

5

821.48

30

0.5

80

5

600

6

1757.98

OBS

DMPG
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21

0.5

60

22

0.5

23

191

(

BIBLIOGRAPHY

(

192

Aoki, F. Y., Crawley,

(

J.

albumin-tecnetium

C. W., "Distribution and removal of human serum

99 m instilled intranasally.," British Journal of

Pharmacology., 3 (1976) 869-879.

Baldwin, P. A., Klingbeil, C. K., Garimm, C.

J.

and Longnecker,

J.

P., "The

effect of sodium tauro-24-25, dihydrofusidate on the nasal absorption of
human growth hormone in three animal models," Pharmaceutical Research.,
7(5) (1990) 547-552.

Balin, B.

J., Broadwell,

R. D., Sakman, M., and El- Kalliny, M. "Avenues for

entry of peripherally administered protein to the central nervous system in
mouse, rat and squirrel monkey," Journal of Computational Neurology., 251
(1986) 260.

(

Banga, A. K. and Chien, Y. W., "Iontophoretic delivery of drugs:
fundamentals, developments and biomedical application.," Journal of
Controlled Release .. 7 (1988) 1.

Burnette, R. R. and Marerro, D., "Comparison between the iontophoretic and
passive transport of thyrotropin releasing hormones across excised nude
mouse skin.," Journal of Pharmaceutical Sciences., 75 (1986) 738-743.

Chien, Y. W., Lelawongs, P., Siddiqui, 0., Sun, Y. and Shi, W. M., "Facilitated
transdermal delivery of therapeutic peptides and proteins by iontophoretic
delivery device.," Journal of Controlled Release., 13 (1990) 263.

(

193

Chien, Y. W ., Su, K. S. E. and Chang, S., (Eds), Physicochemical

(

Biopharmaceutical and Toxicophysiological Considerations in Nasal Systemic
Drug Delivery., Published by Marcel Dekker, (1989) pp. 53

Chien, Y. W ., Su, K. S. E. and Chang, S., (Eds), Physicochemical
Biopharmaceutical and Toxicophysiological Considerations in Nasal Systemic
Drug Delivery .. Marcel Dekker., Inc., NY., (1989) pp. 64

Chien, Y. W ., Su., K. S. E., Chang, S., (Eds.,) Nasal Systemic Drug Delivery.
Physicochemical. Biopharmaceutical and Toxicophysiological
Considerations .. Marcel Dekker, Inc., NY., (1989) pp 49.

Chiou, C. Y. and Chang, M. S., "Systemic delivery of enkephalin.," Life
Sciences., 43 (1988) 509.
(
Chiou, G. C. Y., Chuang, C. Y., and Chang, M. S., "Reduction of blood glucose
concentration with insulin eye drops.," Diabetes Care .. 11 (1988) 750.

Chiou, G. C., and Ching, Y. C., "Improvement of systemic absorption of
insulin through eyes with absorption enhancers.," Journal of Pharmaceutical
Sciences., 78 (1989) 815.

Chiou, G. C., and Chuang, C. Y. and Chang, M.S., "Reduction of blood glucose
concentrations with insulin eye-drops.," Diabetes Care .. 11 (1988) 750.

Chiou, G .C. and Chuang, C. Y., "Treatment of hypoglycemia with glucagon
eyedrops.," Journal of Ocular Pharmacology .. 4 (1989) 179.

194

Christiansen, C., Christiensen, M . S. Larsen, N. E., Transbol, I. B.,

(

"Pathophysiological mechanisms of estrogen effect on bone metabolism.
Dose-response relationships in early postmenopausal women.," Journal of
Clinical Endocrinology and Metabolism., 55 (1982) 1124-1130.

Clark, A. R., "Invitro Assessment of spacer devices.," Presented at Respiratory
Drug Delivery II. Keystone, CO., (1990) March 26-30

Clissod, S. P ., Fitton, A., Chrisp, Paul., "Intranasal salmon calcitonin-A review
of its pharmacological properties and potential utilities in metabolic bone
disorders associated with aging.," Drugs and Aging .. 1 (5) (1991) 405-423.

Collens, W.S. and Goldziehr, "Absorption of insulin by the nasal mucous
membrane.," Proceedings of Society of Experimental Biology .. 29 (1932) 756.

Crooks, P ., "Lung Peptidases and their activities.," Presented at respiratory
drug delivery II. Keystone, CO., (1990) March 26-30.

Curatolo, W., "The lipoidal permeability barriers of the skin and alimentary
tract.," Pharmaceutical Research., 4 (1987) 271.

Davis, S. S., "Advanced Delivery Systems for Peptides and ProteinsPharmaceutical Considerations.," In Delivery Systems for Peptide Drugs.
Edited by Davis, S., Illum, L., and Tominson. Plenum Press, (1986) pp 45-49,.

(

195

Davis, S. S., "Advanced Delivery Systems for Peptides and Proteins-

(

Pharmaceutical Considerations.," In Delivery Systems for Peptide Drugs.
Edited by Davis, S., Illum, L., and Tominson. Plenum Press (1986) pp 76-79.

Davis, S. S., "Advanced Delivery Systems for Peptides and ProteinsPharmaceutical Considerations.," In Delivery Systems for Peptide Drugs.
Edited by Davis, S., Illum, L., and Tomlinson., E., Plenum Press (1986) pp 1.

Davis, S. S., "Advanced Delivery Systems for Peptides and ProteinsPharmaceutical Considerations.," In Delivery Systems for Peptide Drugs.
Edited by Davis, S., Illum, L., and Tomlinson., E., Plenum Press, (1986) pp 265275.

De Boer, A.G., Van Hoogdalem, E.

J., Heijligers-Feijen, C. D., Verhoef, J.C.

and Breimer, D. D., "Rectal Absorption enhancement of peptide drugs.,"
Journal of Controlled. Release., 13 (1990) 241.

deLeede, L. G. J. et al., "Rectal and intravenous propranol infusion to steady
state: Kinetics

and~

receptor blockade.," Clinical Pharmacology and

Therapeutics., 35 (1984) 148-155.

deLeede, L. G.

J., et al., "Enhancement of rectal absorption of insulin using

salicylate in dogs.," Journal of Pharmacokinetics and Biopharrnaceutics .. 10
(1982) 525-537.

Deruloo, M.

J. M., Hermens, W. A. J. J., Romeyn, S. G., Verhoef, J. C., Merkus,

F. W . H . M., "Absorption Enhancement of Intranasally Administered Insulin

(

196

by Sodium Taurodihydrofusidate in Rabbits and Rats.," Pharmaceutical

(

Research., 6 (10) (1982) 853-856.

Donovan, M. D., Flynn, G. L. and Amidon, G. L., "The molecular weight
dependence of nasal absorption: The effect of absorption enhancers.,"
Pharmaceutical Research .. 7(8) (1990) 808-815

Dua, R, Zia, H., Needham, T., "Evaluation of formulation and device
variables on nasal spray characteristics.," Manuscript in Preparation (1995).

Epand, R. M., Epand, R. F., Orlowski, R. C., "Presence of an amphipathic
helical segment and its relationship to biological potency of cakitonin
analogs.," International Journal of Peptides and Protein Research., 25(1) (1993)
105-111.

Epand, R. M., Epand, R. F., Stafford, A. R., Orlowski, R. C., "Deletion
sequences of salmon cakitonin that retain the essential biological and
conformational features of the intact molecule.," Journal of Medicinal
Chemistry .. 31(8) (1988) 1595-1598.

Epand, R., Epand, R. F., Orlowski, R. C., Flanigan., E, Stahl, Glenn, L., "A
comparison of the interaction of glucagon, human parathyroid

hormone-(1-

34) peptide and cakitonin with dimyristoylphosphatidylglycerol and with
dimyristoylphosphatidykholine.," Biophysical Chemistry .. 23 (1-2) (1993) 3948.

197

Evans, W. S., Borges,
r

J.

L. C., Kaiser, D. L., Vance, M. L., Seller, R. P., Macleod,

R. M., Vale, W., Rivier,

J. and Thorner, M. 0., "Intranasal administration of

human pancreatic tumor GH-releasing factor-40 stimulates GH release in
normal men.," Journal of Clinical Endocrinology and Metabolism .. 57 (1983)
1081-1084.

Gansslen, M., "Ueber, inhalation van insulin.," Klin Schnschr .. 4 (1925) 71.

Gizurason, S., "Animal models for intranasal drug delivery studies.," Acta
Pharmaceutical Nordic .. 2(2) (1990) 105-122.

Grossman, A., Fabbri, A., Goldberg, P. L. and Nesser, G. M., 'Two new modes
of desmopressin administration.," British Medical Journal.. 280 (1980) 1215.
(

Hanskiss,

J. and Hadhazy, C.S., "Resorption von insulin and asthmolysin von

der nasenschleimhaut.," Acta. Med. Acad.Sci-Hung .. 12 (1958) 107.

Hanson, M., Gazdick, G., Cahill,

J., Augustine, M., "Intranasal delivery of the

peptide, salmon calcitonin.," In Davis et al, (Eds.,) Delivery systems for
peptide drugs .. Plenum Press, New York (1986) pp. 232-242.

Hardy,

J.

G., Lee, S. W., Wilson, C. G., "Intranasal drug delivery by spray and

drops.," Journal of Pharmacy and Pharmacology .. 37 (1985) 294-297.

Harris, A. S., "Biopharmaceutical aspects of the intranasal administration of
peptides.," in Delivery Systems for Peptide Drugs. Davis, S. S., Illum, L., and
Tomlinson, E., Eds., Plenum Press, NewYork, (1986) pp 191.

198

Harris, A. S., Ohlin, M., Lethagen, S. and Nilsson, I. M., "Effects of

(

concentration and volume on nasal bioavailability and biological response to
Desmopressin.," Journal of Pharmaceutical Sciences., 77(4) {1988) 337-348.

Harris, A.S., Svensson, E., Lethagen, S., and Nilsson, "Effect of viscosity on
Particle Size, Deposition and Clearance of Nasal Delivery Systems Containing
Desmopressin.," Journal of Pharmaceutical Sciences., 77(5) (1988) 405-408.

Hayashi, M., Hirasawam T., Muraoka, T., Shiga, M., and Awazum S.,
"Comparison of water influx and sieving coefficient in rat jejuna!, rectal and
nasal absorption of antipyrine.," Chemical and Pharmaceutical Bulletin., 33
(1985) 2149.

Hendricks, C., and Gabel, R. A. "Use of intranasal oxytocin in obstetrics I.
(

Laboratory evaluation.," American Journal of Obstetrics and Gynecology., 79
(1960) 780.

Hermens, W. A.

J.

J., Hooymans, P. M., Verhoef, J. C., Merkus, F. W. H.,

"Effects of absorption enhancers on human nasal tissue ciliary movement in
vitro.," Pharmaceutical Research., 7 (2) (1990) 144-146.

Heubner, W., deJough, S.E., and Laquer, E., "Ueber inhalation von insulin.,"
Klin Schnshr., 3 (1924) 2342.

Hirai, S., Yashiki, T and Mirna H., "Mechanisms for the enhancement of the
nasal absorption of insulin by surfactants.," International Journal of
Pharmaceutics., 9 (1984a) 173.

199

Hirai, S., Yashiki, T., and Mirna, H., "Effect of surfactants on the nasal
(

absorption of insulin in rats.," International Journal of Pharmaceutics .. 9
(1981a) 165.

Hirai, S., Yashiki, T., Mirna, H., "Effect of surfactants on the nasal absorption
on insulin on rats.," Journal of Pharmaceutical Sciences .. 9 (1981) 165-172.

Hirai, S., Yashiki, T., Mirna, H., "Vaginal absorption of a potent luteinizing
hormone -releasing hormone analog (leuprolide) in rats I : Absorption by
various routes and absorption enhancement.," Journal of Pharmaceutical
Sciences .. 71 (1982) 1367-1370.

Hughes, B.L., Allen, D. L., Dorato, M.A and Wolff, R.K., "Effects of delivery
devices on nasal deposition and mucociliary clearance in rhesus monkey.,"

(

Journal of Aerosol Science and Technology .. 18 (1993) 241-249

Hussain, A. A., Hirai, S and Bawarshi, R., "Nasal absorption of natural
contraceptives steroids in rats-Progesterone absorption.," Journal of
Pharmaceutical Sciences .. 70 (1981) 466.

Hussain, A. A., Hirai, S., Kashihara, T., Batenhorst, R., et al., "Nasal
Absorption of propranolol in humans., Journal of Pharmaceutical Sciences.,
69 (1989) 1240.

Hussain, A. A., Kimura, R., and Huang, C. H., "Nasal absorption of
testosterone in rats.," Journal of Pharmaceutical Sciences .. 73 (1984) 1300.

200

Ilium, L., Farraj, N. F., Critchley, H., Johansen, B. R. and Davis, S. S.,

(

"Enhanced nasal absorption of insulin in rats using
lysophosphatidykholine.," International Journal of Pharmaceutics .. 57 (1989)
49-54.

Illlum, L., Farraj, N. F., Davis, S. S., Johansen, B. R. and O'Hagen, D. T.,
"nvestigation of the nasal absorption of biosynthetic human growth in sheep
- use of a bioadhesive microsphere delivery system.," International Journal of
Pharmaceutics .. 63 (1990) 207-211.

Ilium, L., "Microspheres as a potential controlled release nasal drug delivery
systems" in Delivery systems for peptide drugs .. Davis, S. S., Illum, L. and
Tomlinson, E., Plenum Press, New York, (1980) pp. 205-210.

Jager--Waldau, R., "A Two Phase Flow Mechanical Spray Pump: A possible
alternative to propellant driven MDI's.," Journal of Biopharmaceutical
Sciences .. 3(1/2) (1992) 77-84

Juhasz, J., Lenaerts, V., and Ong, H ., "Poloxamer gels for peptide delivery- in
vitro studies.," Journal of Controlled Release., 13 (1990) 322.

Kajii, H., Horie, T., Hayashi, M. and Awazu, S., "Fluorescence study on the
interaction of salicylate with rat small intestinal epithelal cells: possible
mechanisms for the promoting effects of salicylate on drug absorption in
vivo.," Life Sciences .. 37 (1985) 523.

201

Kamada., Nishihata, T., Kim, S., Yamamoto, M. and Yata, N., "Study of

(

enamine derivatives of phenylglycine as adjuvants for the rectal absorption
of insulin.,"Chemical and Pharmaceutical Bulletin .. 29 (1980) 2012.

Kamada, A., Nishihata, T., Kimu, S., Yamamoto, M. and Yata, N., "Study of
enamine derivatives of phenylglycine as adjuvants for the rectal absorption
of insulin.," Chemical and Pharmaceutical Bulletin .. 29 (1981) 2012-2019.

Kari, B., "Control of blood glucose levels in alloxan-diabetic rabbits by
iontophoresis of Insulin.," Diabetes .. 35 (1986) 217-221.

Keenan,

J. and Chamberlain, M. A. "Nasal mucosa! absorption of

tetracosactrin as indicated by rise in plasma flurogenic corticosteroids.,"
British Medical Journal.. 4 (1969) 407-408.

(
Kim, S., Kamada, A., Higuchi, T. and Nishihata, T., "Effects of enamine
derivatives on the rectal absorption of insulin in dogs and rabbits.," Journal of
Pharmacy and Pharmacology .. 35 (1983) 100.

Kurose, H., Seino, Y., Shima, M., Tanaka, H., Ishiiida, M. et al, "Intranasal
absorption of salmon calcitonin.," Calcified Tissue International.. 41 (1987)
249-251.

Law, P.Y., Harris, R. A., Loh, H.H.,

and Way, E. L., "Evidence for the

involvement of cerebroside sulfate in opiate receptor binding.," Journal of
Pharmacology and Experimental Therpeutics .. 207 (1978) 458.

202

Lee, V. H. L., Carson, L. W., Dodda-Kashi, S. and Stratford, R. E., "Metabolic

(

permeation barriers to the ocular absorption of topically applied enkephalins
in albino rabbits.," Journal of Ocular Pharmacology .. 4 (1989) 179.

Lee, V. H. L., "Enzymatic barriers to peptide and protein absorption and use of
penetration enhancers to modify absorption.," In Delivery Systems for
Peptide Drugs. Edited by Davis, S. S., Illum, S.S., Tomlinson, E., (1986) pp. 87104,.

Lee, V. H. L., "Mechanisms and facilitation of corneal drug penetration.,
Journal of Controlled Release .. 11 (1991) 79-84.

Lee, V. H. L., "Peptide and Protein Drug Delivery Systems.," Biopharm .. 1(3)
(1988) 24-31.

Lee, W. A., "Permeation Enhancers for the nasal delivery of protein and
peptide therapeutics.," Biopharm., 3 (10) (1990) 22-25.

Lee, W.A., Ennis, RD., Longnecker, J.P., and Bengtsson, P., "The
bioavailability of intranasal salmon calcitonin in healthy volunteers with and
without a permeation enhancer.," Pharmaceutical Research., 11(5) 1994.

Levy, R. S., "Efficient Calcitonin Production.," Biopharm .. May (1993) 36-39.

London, D. L., Butt, W. R., Lynch, S. S., Marshall, J. C., Robinson, W. R. and
Stephanson, J. M., "Hormonal response to intranasal luteinizing hormone

203

releasing hormone.," Journal of Clinical and Endocrinology Metabolism .. 37

(

(1973) 829-831.

Longnecker, J.P., Moses, A. C., Flier, J. S., Silver, R. D., Carey, M. C., Dubov, E.
J., "Effects of sodium taurodihydrofusidate on nasal absorption of insulin in
sheep.," Journal of Pharmaceutical Sciences., 76(5) (1987) 351- 355.

Longnecker, J. P., Moses, A. C., Flier, J. S., Silver, R. D., Carey, M.C. and
Dubovi, E. J., "Effects of sodium taurodihydrofusidate on nasal absorption of
insulin in sheep.," Journal of Pharmaceutical Sciences .. 76 (1987) 351-355.

Major, R. H., "The intranasal application of insulin, experimental and clinical
experiences.," American Journal of Medical Science .. 192 (1936) 257.

Martin, G. P., Marriott., C., Kellaway, I. W., "Direct effects of bile salts and
phospholipids on the physical property of mucus.," GYL 19 (1978) 103.

Merkle, H ., Anders, R., Wermerskirchen, A., Rachs, S., and Wolany, G., .
"Buccal routes of peptides and protein drug delivery" in Peptide and Protein
Drug Delivery., Lee, V. H . L., Ed., Marcel Dekker, New York (1991) Chap.11.

Milhaud, G., Tsieng-Ming, Nesralla, H., Moukhtar, M.S., Perault-Staub, A. M.,
"Studies on the mode of action and the therapeutic use of thyrocalcitonin" in
Taylor, S. F., (Eds.) Calcitonin, Heinemann, London (1967) pp. 347,

204

Miller, L., Kolaskie, C.J., Smith, G. A., and Riviere, J., "Transdermal

(

iontophoresis of gonadotrophin releasing hormone (LHRH) and two
analogues.," Journal of Pharmaceutical Sciences .. 79 (1990) 490.

Mishima, M., Wakita, Y, and Nakano, "Studies on the promoting effects of
medium chain fatty acids salts on the nasal absorption of insulin in rats.,"
Journal of Pharmacobiodynamics., 10 (1990) 624-631.

Mohamadi, M., Becker, K. L., and Bivins, L. E., "Paradoxical Effects of Salmon
Calcitonin

on

serum

calcium:

Studies

on

intact

and

Thyroparathroidectomized men and dogs.," Acta Endocrinologica .. 79 (1975)
700-708.

Morimoto, K., et al., "Enhanced rectal absorption of [Asu 1,7]-eel cakitonin in
rats using polyacrylic acid aqueous gel base.," Journal of Pharmaceutical
Sciences .. 73 (1984) 1366-1368.

Morimoto, K., Morisaka, K., and Kamada, "Enhancement of nasal absorption
of insulin and cakitonin using polyacrylic acid gel.," Journal of Pharmacy and
Pharmacology .. 37 (1985) 134-136.

Morvola, M., Reinikaine, A., Heliovaara, M., Huikari, A. J., "The effects of
some sweetening agents and osmotic pressure on the intestinal absorption of
sulfafurazole in the rat.," Journal of Pharmacy and Pharmacology.,31 (1979)
615.

(

205

Moses, A. M., "Synthetic lysine vasopressin nasal spray in the treatment of

(

diabetes insipidus," Lancet, 1 (1964) 422.

Moses, A.C., Gorson, G. S., Carey, M. C. and Flier,

J.

S., "Insulin administered

intranasally as an insulin-bile salt erosol: effectiveness and reproducibility in
normal and diabetic subjects.," Diabetes. 32 (1977) 1040.

Muller, K., Osler, M., "Induction of labor, a comparison of intravenous,
intranasal and transbuccal oxytocin.," Acta Obstetrics . Gynecology.
Scandanavia., 46 (1967) 59-67.

Murakami, T., Yata, N., Tamauchi, J. Nakai, Yamazaki, M and Kamada, A.,
'Studies on absorption promoters for rectal delivery preparations. I.
Promoting efficacy of enamine derivative of amino acids for the rectal

(

absorption of iS- lactam antibiotics in rabbits.," Chemical and Pharmaceutical
Bulletin .. 29 (1981) 1998-2004.

Muranushi, N., Takagi, N ., Muranishi, S. and Sezak, H., "Effect of fatty acids
and monoglycerides on permeability of lipid bilayer.," Chemical Physical
Lipids .. 28 (1981) 269.

Muraushi, N., Nakajima, Y., Kinugawa, M.,

Muranishi, S., Sezaki, H.,

"Mechanism for the inducement of the intestinal absorption of poorly
absorbed drugs by mixed micelles II. Effects of the incorporation of various
lipids on the permeability of liposomal membranes.," International Journal
of Pharmaceutics .. 4 (1982) 281.

206

Salzman, R., Manson,
(

J.

E., Griffing, G. T., Kimmerle, R., Ruderman, N., et al.,

"Intranasal aerosolizedd insulin, mixed meal studies and long term use in
type I diabetes.," New England Journal of Medicine. 312 (1985) 1078-1084 .

Sekine, M., Sasahara, K., Kojima, T., Hasegawa, K., and Okada, R.,
"Improvement of bioavailability of poorly intestinally absorbed drugs from
medium chain glyceride base : Enhancement of the rectal absorption of
cefmetazole sodium in rabbits.," Chemical and Pharmaceutical Bulletin .. 32
(1984) 4189-4192.

Shao, Z., Krishnamoorthy, R., and Mitra, A. K., "Cyclodextrins as nasal
absorption promoters of insulin: Mechanistic Evaluations.," Pharmaceutical
Research., 9 (9) (1992) 1157-1163.

Siddiqui, 0., et al ., "Facilitated transdermal transport of insulin.," Journal of
Pharmaceutical Sciences .. 76 (1987) 341-345.

Sithigorngul, P., Burton, Nishhata, T., and Caldwell, L., "Effects of sodium
salicylate on epithelial cells

of the rectal mucosa of the rat:

a light and

electron microscopy study.," Life Sciences .. 33 (1983) 1025.

Srinivasan, V., Su, M. H., Higuchi, W. I., and Behl, C. R., "Iontophoresis of
polypeptides: effects of ethanol pretreatment of human skin.," Journal of
Pharmaceutical Sciences .. 79 (1990) 588.

Stafford, R. E., and Dennis, E. A., "Lysophospholipids as biosurfactants.,"
Colloids and surfaces .. 30 (1988). 47-64.

207

Pontiroli, A. E., Secchi, A., and Alberetto, M., "Alternative routes of peptide

(

hormone administration.," Special Topics Endocrinology. Metabolism .. 7
(1985) 77.

Pujara, C. P., Shao, Z., Duncan, M. R., and Mitra, A. K., "Effects of formulation
variables on nasal epithelial cell integrity: Biochemical evaluations.,"
International Journal of Pharmaceutics .. 114 (1995) 197-203.

Rytting, H., "Rectal route of peptide and protein drug delivery.," in Peptide
and Protein Delivery. Lee. V. H. L., Ed., Marcel Dekker, New York., (1989) pp
579.

Saffran, M., et al., "A new approach to the oral administration of insulin and
other peptide drugs.," Science., 233 (1986) 1081-1084.

Saikiya, Y., Miyauchi., Y., Tsuemura, Y. "Influence of osmotic Pressure and
Viscosity on intestinal Drug Absorption. II Quinine Concentration profile in
plasma after oral administration of variousQuinine solutions to Rats.,"
Chemical and Pharmaceutical Bulletin .. 29 (1981) 1470-1472

Sakai, K., Kutsuna, T. M., Nishino, T., Fufihara, Y.,

and Yata, N.,

"Contribution of calcium ion sequestration by polyoxyethylated non-ionic
surfactants to the enhanced colonic absorption of p-aminobenzoic acid.",
Journal of Pharmaceutical Sciences., 75 (1986) 387.

208

Ohwaki, T., Ando, H ., Watanabe, S. and Miyake, Y., "Effects of dose, pH, and

(

osmolarity on nasal absorption of secretin in Rats.," Journal

of

Pharmaceutical Science., 74 (1985) 550-552.

Okada, H., Yamazaki, I., Ogawa, Y., Hirai, S., Yashiki, T., and Mirna, H.

J.,

"Vaginal absorption of a potent luteinizing hormone- releasing hormone
analog (leuprolide) in rats. I. Absorption by various routes and absorption
enhancement.," Journal of Pharmaceutical Sciences., 72 (1982) 75.

Park, G. B., Shao, Z . and Mitra, A.K., "Acyclovir permeation enhancement
across intestinal and nasal mucosae by bile salt-acykarnitine mixed micelles.,"
Pharmaceutical. Research., 9 (10) (1990) 1262-1267.

Pennington, A.K., Ratcliffe,

J.

H., Wilson, C.G., and Hardy,

J.

G., "The

Influence of solution viscosity on nasal spray deposition and clearance.,"
International Journal of Pharmaceutics., 43 (1988) 221-224.

Pontiroli, A. E., Alberetto, M., Secchi, A., Dossi, G., Bosi, I., and Pozza, G.,
"Insulin given intranasally induces hypoglycaemia in normal and diabetic
subjects.," British Medical Journal.. 284 (1982) 303.

Pontiroli, A. E., Perfetti, M.G., Fattor, B., Pozza, G., "Effect of intranasal growth
hormone releasing hormone and corticotrophic- releasing hormone
administration improved bioavailabilty by means of sodium-glycoholate.,"
Journal of Clinical Metabolism., 68 (1989b) 821-824.

(

209

Mygind, N., and Vesterhauge, S. "Aerosol distribution in the nose.,"

(

Rhinology, 11 (1978) 79-84.

Nagai, T., Nishimoto, Y., Nambu, N., Suzuki, Y. and Sekine, K., "Powder
dosage forms of Insulin for nasal administration.," Journal of Controlled
Release .. 1(1984) 15-22.

Newman, S. P., Clark, A. R., Talasee, N., and Clarke, S. W., "Pressurized
inhaler deposition in the human lung with and without an "open" space
device, using a simple radiolabelling technique.," Thorax., 44 (1989) 706.

Nishhata, T., Kim, S., Morishita, S., Kamada, A., Yata, N., and Higuchi, T.,
"Adjuvant effects of glyceryl esters of acetoacetic acid on rectal absorption of
insulin and insulin in rabbits.," Journal of Pharmaceutical Sciences .. 72 (1983)

(

280.

Nishihata, T., et al., "Enhancement of rectal absorption of insulin in dogs
using salcylate in dogs.," Journal of Pharmacy and Pharmacology .. 35 (1983)
148-151.

Nishihata, T., Higuchi, T., and Kamada, A., "Salicylate-promoted permeation
of cefoxition, Insulin and phenylalanine across red cell membrane: Possible
mechanisms.," Life Sciences., 34 (1984a) 437.

Nishihata, T., Lee, C., Yamamoto, M., Rytting, J. H. and Higuchi, T., "The
effect of salicylate in the rectal absorption of phenylalanine and some peptides

210

and the effects of these peptides on the rectal absorption of cefoxin and
cefmetazole.," Journal of Pharmaceutical Sciences .. 73 (1984) 1326-1328.

Nishihata, T., Okamura, Y., Kamada, A., Higuchi, T., Yagi, T., Kawamori, R.,
and Scichiri, M., "Enhanced bioavailability of insulin after rectal
administration with enamine as adjuvant in depancreatized dogs.," Journal
of Pharmacy and Pharmacolgy .. 37 (1985a) 22.

Nishihata, T., Rytting, J. H., Higuchi, T., Caldwell, L., "Enhanced rectal
absorption of insulin and heparin in rats in the presence of non-surfactant
adjuvants.," Journal of Pharmacy and Pharmacology., 33 (1980) 334-335.

Nishimura, K., Nozaki., Y., Yoshimi, A., Nakamura, S., Kitagawa, M., Kakeya,
N., Kitao, K., "Studies in the promoting effects of carboxylic acid derivatives
on the rectal absorption of

~-lactam

antibiotics in rats.," Chemical and

Pharmaceutical Bulletin., 33 (1985) 282 291.

O'Hagan, D. T., Critchley, H., Farraj, N. F., Johansen, B. R., Davis, S. S. and
Illum, L., "Effects of various absorption enhancers on the nasal absorption of
biosynthetic human growth hormone in the rat.," Pharmaceutical Research.,
7 (1990) 772-776.

Oberdorster, G., "Alveolar clearance of inhaled particles and drugs.," Aerosol
Age, January (1991) 34.

211

Stanzani, L., Mascellanio, G., Corbelli, G. P.,

(

and Bianchini, P., "Rectal

absorption of some glycosaminoglycan sulphates and heparin in rats.,"
Journal of Pharmacy and Pharmacology., 33 (1981)783.

Su, K. D. E .. , Oeswein,

J.

and Campanale, K. M., "Intranasal

Q.,

administration of human zinc insulin in rats:Absorption and possible
mechanisms.," A. Journal of Pharmaceutical Academic

Pharmeutical

Sciences., 15 (1985) 89.

Su, K. S. E., Campanale, K. M., Mendelsohn, L. G., Kerchner, G. A., and Gries,
C. L. , "Nasal delivery of polypeptides. I Nasal absorption of enkephalins in
rats.," Journal of Pharmaceutical Sciences., 74 (1985) 394-398.

Su, K. S. E., Howey, D. C., Campanale, K. M., and Oeswein, J. Q., "Intranasal
admininstration of human sodium insulin in rats, dogs and humans:
Absorption and possible mechanisms.," Diabetes., 35 (1986) A 64.

Su, K.S. E., "Nasal route of peptide and protein drug delivery.," in Peptide and
Protein Drug Delivery, Lee, V. H. L., Ed., Marcel Dekker, NewYork, (1991)
Chapter. 13.

Tagesson,

C.,

Franzen,

"Lysophosphatidylcholine
macromolecules.,"

L.,

Dahl,

increases

G,
rat

and
ileal

Westrom,
permeability

B.,
to

.G.!!L 26 (1985) 369-377.

Taniguchi, K., Muranishi, S., and Sezaki, H., "Enhanced intestinal
permeability to macromolecules II. Improvements of the large intestinal

212

absorption of heparin by lipid-surfactant mixed micelles in rat.," International
Journal of Pharamceutical Sciences., 4 (1980) 219.

Tengamnuay, P, and Mitra, A. K., "Bile salt fatty acid mixed micelles: a nasal
absorption promoters of peptides. II In vivo nasal absorption of insulin in rats
and effects of mixed micelles on the morphological integrity of the nasal
mucosa.," Pharmaceutical Research., 7 (1990) 370-375.

Tyle, P., "Iontophoretic devices for drug delivery.," Pharmaceutical Research.,
3 (1986) 318-326.

Vance, M . L., Evans, W. S., Kaiser, D. L., Burke, R. L., Rivier,

J.

et al., "The

effect of intravenous subcutaneous, and intranasal GH-RH analog on growth
hormone secretion in normal men: dose response relationship.," Clinical
Pharmacology and Therapeutics., 40 (1986) 627-633.

Wearley, L. L., "Recent Progress in Protein and Peptide Delivery by
Noninvasive Routes.," Critical Reviews in Therapeutic Drug Carrier
Systems., 8(4) (1991) 331-394.

Woodyatt, R.T., "The clinical use of insulin.," Journal of Metabolism
Research .. 2 (1922) 793.

Yagi, T., Hakui, N ., Yamasaki, y., Kawamori, R., Shichiri, M., Abe, H., Kim, S.,
Miyake, M ., Kamikw awa, K., Nishihata, T., and Kamada, A., "Insulin
suppository: enhanced rectal absorption of insulin using an enamine

213

derivative as a new promoter.," Journal of Pharmacy and Pharamcology .. 37
(

(1985) 512.

Yamamoto, ., Luo, A. M., Dodda-Kashi, S., and Lee, V. H. L., "The ocular route
for systemic insulin delivery in the albino rabbit.," Journal of Pharmacy and
Experimental Therapeutics. 249 (1989) 249.

Yamashita, S., Saitoh, H ., Nakainshi, K., Masada, M., Nadai, T., and Kimura,
T., "Characterization of enhanced intestinal permebility; electrophysiological
study on the effects of diclofenac and ethylenedianinetetraacetic acid.,"
Journal of Pharmacy and Pharmacology. 37 (1985) 512.

Ziegler, R., Holz, G., Strrebl, W and Raue, R., "Nasal applications of calcitonin
in Paget's disease of bone.," Acta Endocrinology Supplement.. 215 (1978) 54-55

214

